EP3728288A1 - Methods for enhanced removal of impurities during protein a chromatography - Google Patents
Methods for enhanced removal of impurities during protein a chromatographyInfo
- Publication number
- EP3728288A1 EP3728288A1 EP18842505.2A EP18842505A EP3728288A1 EP 3728288 A1 EP3728288 A1 EP 3728288A1 EP 18842505 A EP18842505 A EP 18842505A EP 3728288 A1 EP3728288 A1 EP 3728288A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- concentration
- region
- solution
- wash solution
- arginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 201
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 192
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 192
- 239000012535 impurity Substances 0.000 title claims description 89
- 238000004587 chromatography analysis Methods 0.000 title abstract description 33
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims abstract description 321
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 147
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 147
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 147
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims abstract description 133
- 229920001184 polypeptide Polymers 0.000 claims abstract description 110
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 110
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 110
- 235000019445 benzyl alcohol Nutrition 0.000 claims abstract description 107
- 238000003306 harvesting Methods 0.000 claims abstract description 72
- 239000000243 solution Substances 0.000 claims description 411
- 239000004475 Arginine Substances 0.000 claims description 143
- 229960003121 arginine Drugs 0.000 claims description 143
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 143
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 142
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 132
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 115
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 103
- 239000011159 matrix material Substances 0.000 claims description 72
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 71
- 229960002446 octanoic acid Drugs 0.000 claims description 71
- 229940051250 hexylene glycol Drugs 0.000 claims description 66
- 235000019846 buffering salt Nutrition 0.000 claims description 65
- 241000282414 Homo sapiens Species 0.000 claims description 63
- 238000005406 washing Methods 0.000 claims description 59
- 229940077388 benzenesulfonate Drugs 0.000 claims description 57
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 57
- 229960003624 creatine Drugs 0.000 claims description 57
- 239000006046 creatine Substances 0.000 claims description 57
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 54
- 239000011780 sodium chloride Substances 0.000 claims description 53
- 239000012504 chromatography matrix Substances 0.000 claims description 46
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical group OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 34
- 229960003589 arginine hydrochloride Drugs 0.000 claims description 33
- 239000007983 Tris buffer Substances 0.000 claims description 31
- 239000000872 buffer Substances 0.000 claims description 31
- 239000008363 phosphate buffer Substances 0.000 claims description 28
- 238000010828 elution Methods 0.000 claims description 26
- 239000006172 buffering agent Substances 0.000 claims description 24
- 229910019142 PO4 Inorganic materials 0.000 claims description 22
- 239000010452 phosphate Substances 0.000 claims description 22
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 21
- -1 benzoate alkali salt Chemical class 0.000 claims description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 229940077386 sodium benzenesulfonate Drugs 0.000 claims description 15
- MZSDGDXXBZSFTG-UHFFFAOYSA-M sodium;benzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC=CC=C1 MZSDGDXXBZSFTG-UHFFFAOYSA-M 0.000 claims description 15
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 15
- 238000011118 depth filtration Methods 0.000 claims description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- 238000001042 affinity chromatography Methods 0.000 claims description 12
- 239000001488 sodium phosphate Substances 0.000 claims description 11
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 11
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 11
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 10
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 9
- 102000003780 Clusterin Human genes 0.000 claims description 9
- 108090000197 Clusterin Proteins 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 102000015439 Phospholipases Human genes 0.000 claims description 8
- 108010064785 Phospholipases Proteins 0.000 claims description 8
- 241000699802 Cricetulus griseus Species 0.000 claims description 7
- 102100036164 Putative phospholipase B-like 2 Human genes 0.000 claims description 7
- 101710200837 Putative phospholipase B-like 2 Proteins 0.000 claims description 7
- 102000012479 Serine Proteases Human genes 0.000 claims description 7
- 108010022999 Serine Proteases Proteins 0.000 claims description 7
- 210000001672 ovary Anatomy 0.000 claims description 7
- 239000008351 acetate buffer Substances 0.000 claims description 6
- 239000007979 citrate buffer Substances 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 5
- 235000011164 potassium chloride Nutrition 0.000 claims description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 101710120037 Toxin CcdB Proteins 0.000 claims description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims description 4
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 229910001622 calcium bromide Inorganic materials 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 claims description 2
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 claims description 2
- 229910001623 magnesium bromide Inorganic materials 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 238000000746 purification Methods 0.000 abstract description 28
- 235000018102 proteins Nutrition 0.000 description 182
- 229960003885 sodium benzoate Drugs 0.000 description 132
- 235000009697 arginine Nutrition 0.000 description 131
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 80
- 210000004027 cell Anatomy 0.000 description 61
- 239000000523 sample Substances 0.000 description 48
- 150000001483 arginine derivatives Chemical class 0.000 description 27
- 229920005989 resin Polymers 0.000 description 27
- 239000011347 resin Substances 0.000 description 24
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 23
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 21
- 238000002965 ELISA Methods 0.000 description 17
- 238000004113 cell culture Methods 0.000 description 15
- 108060003951 Immunoglobulin Proteins 0.000 description 14
- 239000000654 additive Substances 0.000 description 14
- 102000018358 immunoglobulin Human genes 0.000 description 14
- 239000000047 product Substances 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 238000011068 loading method Methods 0.000 description 11
- 239000005711 Benzoic acid Substances 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 235000010233 benzoic acid Nutrition 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 239000012560 cell impurity Substances 0.000 description 9
- 239000008055 phosphate buffer solution Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000004949 mass spectrometry Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 6
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- 241000699800 Cricetinae Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 6
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- 229940050390 benzoate Drugs 0.000 description 6
- 239000012539 chromatography resin Substances 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- OGGXGZAMXPVRFZ-UHFFFAOYSA-N dimethylarsinic acid Chemical compound C[As](C)(O)=O OGGXGZAMXPVRFZ-UHFFFAOYSA-N 0.000 description 6
- 238000011143 downstream manufacturing Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000011067 equilibration Methods 0.000 description 6
- 239000001632 sodium acetate Substances 0.000 description 6
- 235000017281 sodium acetate Nutrition 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 239000004695 Polyether sulfone Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229920006393 polyether sulfone Polymers 0.000 description 5
- 239000012085 test solution Substances 0.000 description 5
- 238000012855 HCP-ELISA Methods 0.000 description 4
- 239000012515 MabSelect SuRe Substances 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000012516 mab select resin Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000012562 protein A resin Substances 0.000 description 4
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- 239000007993 MOPS buffer Substances 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000007990 PIPES buffer Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 3
- 239000007997 Tricine buffer Substances 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000011091 antibody purification Methods 0.000 description 3
- 239000007998 bicine buffer Substances 0.000 description 3
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 3
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 3
- 229950004243 cacodylic acid Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- VDEGQTCMQUFPFH-UHFFFAOYSA-N hydroxy-dimethyl-arsine Natural products C[As](C)O VDEGQTCMQUFPFH-UHFFFAOYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000001223 reverse osmosis Methods 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- DGOAYHVIVJYHKU-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrochloride Chemical compound Cl.NC(=N)N(C)CC(O)=O DGOAYHVIVJYHKU-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000002242 deionisation method Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000004300 potassium benzoate Substances 0.000 description 2
- 235000010235 potassium benzoate Nutrition 0.000 description 2
- 229940103091 potassium benzoate Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004886 process control Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000011012 sanitization Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000012536 storage buffer Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- IKOCUOZSKMSIPP-UHFFFAOYSA-N 2-(2-ethylpiperazin-1-yl)ethanesulfonic acid Chemical compound CCC1CNCCN1CCS(O)(=O)=O IKOCUOZSKMSIPP-UHFFFAOYSA-N 0.000 description 1
- MBBREGJRSROLGD-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound NC(=N)N(C)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MBBREGJRSROLGD-UHFFFAOYSA-N 0.000 description 1
- DLNGCCQFGNSBOP-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.NC(=N)N(C)CC(O)=O DLNGCCQFGNSBOP-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SWKVSFPUHCMFJY-UHFFFAOYSA-N 6-methyl-2-oxo-5-pyridin-4-yl-1h-pyridine-3-carboxamide Chemical compound N1C(=O)C(C(N)=O)=CC(C=2C=CN=CC=2)=C1C SWKVSFPUHCMFJY-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical group Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 1
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 1
- 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 229930028154 D-arginine Natural products 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- SNEIUMQYRCDYCH-UHFFFAOYSA-N acetylarginine Chemical compound CC(=O)NC(C(O)=O)CCCN=C(N)N SNEIUMQYRCDYCH-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- MJIAXOYYJWECDI-UHFFFAOYSA-L barium(2+);dibenzoate Chemical compound [Ba+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 MJIAXOYYJWECDI-UHFFFAOYSA-L 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000004301 calcium benzoate Substances 0.000 description 1
- 235000010237 calcium benzoate Nutrition 0.000 description 1
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- BLUMOBPWAAOPOY-UHFFFAOYSA-M cesium;benzoate Chemical compound [Cs+].[O-]C(=O)C1=CC=CC=C1 BLUMOBPWAAOPOY-UHFFFAOYSA-M 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 101150036359 clpB gene Proteins 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940031993 lithium benzoate Drugs 0.000 description 1
- LDJNSLOKTFFLSL-UHFFFAOYSA-M lithium;benzoate Chemical compound [Li+].[O-]C(=O)C1=CC=CC=C1 LDJNSLOKTFFLSL-UHFFFAOYSA-M 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- PJJZFXPJNUVBMR-UHFFFAOYSA-L magnesium benzoate Chemical compound [Mg+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 PJJZFXPJNUVBMR-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012434 mixed-mode chromatography Methods 0.000 description 1
- 238000012433 multimodal chromatography Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- RCXZWRSKKKLCPO-UHFFFAOYSA-M rubidium(1+);benzoate Chemical compound [Rb+].[O-]C(=O)C1=CC=CC=C1 RCXZWRSKKKLCPO-UHFFFAOYSA-M 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- RDRLLHKVJZUFIB-UHFFFAOYSA-L strontium;dibenzoate Chemical compound [Sr+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 RDRLLHKVJZUFIB-UHFFFAOYSA-L 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/424—Elution mode
- B01D15/426—Specific type of solvent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Definitions
- the present disclosure relates to methods of purifying a polypeptide comprising an Fc region (e.g ., an antibody) via protein A chromatography.
- Fc region e.g ., an antibody
- Antibodies, and other Fc region-containing proteins have found widespread use in pharmaceutical/therapeutic applications.
- the use of these molecules e.g., in human patients
- Purification of therapeutic proteins is often achieved utilizing one or more chromatographic purification steps; a particularly useful type of chromatographic purification of proteins that contain an immunoglobulin Fc region (e.g, an antibody) is protein A chromatography.
- host cell proteins HCPs
- one or more wash steps are employed following binding of the product (e.g, a protein containing an immunoglobulin Fc region)
- a Protein A chromatography matrix with a sample (e.g ., a cell lysate) comprising (i) a polypeptide comprising an Fc region and (ii) one or more impurities, and washing the matrix with a wash solution having a pH of about 4.0-10.0 and comprising a benzoate salt and/or benzyl alcohol.
- a sample e.g ., a cell lysate
- a wash solution having a pH of about 4.0-10.0 and comprising a benzoate salt and/or benzyl alcohol.
- the present disclosure is based, at least in part, on the surprising finding that use of benzoate salt (e.g., sodium benzoate) and/or benzyl alcohol in a wash solution at a pH of about 4.0-10.0 during protein A chromatography provides superior clearance of impurities (e.g, host cell impurities) over currently utilized wash formulations (See FIG. 1, Example 1).
- the present disclosure is also based, at least in part, on the finding that the inclusion of one or more additional components selected from benzenesulfonate (e.g, sodium benzenesulfonate), caprylic acid, hexylene glycol, and/or arginine may further improve the clearance of impurities when included in the wash solution (See FIGS. 2 and 3, Example 1).
- a method of purifying a polypeptide comprising an Fc region comprising the steps of: (a) contacting a Protein A chromatography matrix with a sample comprising (i) the polypeptide comprising the Fc region and (ii) one or more impurities, under a condition that the polypeptide comprising the Fc region binds to Protein A; and (b) washing the matrix with a wash solution, wherein the wash solution comprises one or both of (i) a benzoate salt at a concentration of about 0.1 M to about 1.0 M and (ii) benzyl alcohol at a concentration of about 0.5% to about 4% volume/volume (v/v), and wherein the wash solution has a pH of about 4.0 to about 10.0.
- the wash solution comprises: (1) benzoate salt; (2) benzyl alcohol; or (3) benzoate salt and benzyl alcohol.
- the benzoate salt is at a concentration from about 0.1 M to about 0.5 M.
- the benzoate salt is a benzoate alkali salt. In some embodiments that may be combined with any of the preceding
- the benzoate salt is sodium benzoate.
- the sodium benzoate is at a concentration from about 0.1 M to about 0.3 M. In some embodiments, the sodium benzoate is at a concentration of about 0.3 M. In some embodiments, the sodium benzoate is at a concentration of about 0.5 M.
- the benzyl alcohol is at a concentration from about 1% to about 4% (v/v). In some embodiments that may be combined with any of the preceding embodiments, the benzyl alcohol is at a concentration from about 1% to about 2% (v/v).
- the benzyl alcohol is at a concentration of about 2% (v/v). In some embodiments that may be combined with any of the preceding embodiments, the benzyl alcohol is at a concentration of about 4% (v/v).
- the wash solution further comprises a buffering agent.
- the buffering agent is selected from phosphate, tris, arginine, acetate, and citrate.
- the buffering agent is at a concentration of about 10 mM to about 50 mM or about 10 mM to about 500 mM. In some embodiments, the buffering agent is at a
- the buffering agent is at a
- the wash solution has a pH of about 5.0 to about 10.0. In some embodiments, the wash solution has a pH of about 5.0 to about 9.0. In some embodiments, the wash solution has a pH of about 5.0, about 6.0, about 7.0, about 8.0, about 9.0, or about 10.0.
- the wash solution further comprises sodium benzenesulfonate.
- the sodium benzenesulfonate is at a concentration of about 0.1 M to about 0.5 M.
- the wash solution further comprises caprylic acid.
- the caprylic acid is at a concentration of about 10 mM to about 50 mM.
- the wash solution further comprises hexylene glycol.
- the hexylene glycol is at a concentration of about 1% to about 10% (v/v).
- the wash solution further comprises creatine.
- the creatine is at a concentration of about 10 mM to about 100 mM.
- the wash solution further comprises arginine.
- the arginine is at a concentration of about 0.1 M to about 1.0 M.
- the arginine is at a concentration of about 0.5 M.
- the arginine is arginine-HCl.
- the wash solution comprising arginine has a pH of about 4.0 to about 6.0.
- the wash solution comprising arginine has a pH of about 8.0 to about 10.0.
- the wash solution further comprises one or more non-buffering salts.
- the one or more non- buffering salts are selected from sodium chloride, sodium bromide, potassium chloride, potassium bromide, magnesium chloride, magnesium bromide, calcium chloride, calcium bromide, and any combinations thereof.
- the one or more non- buffering salts are sodium chloride and/or potassium chloride.
- the one or more non-buffering salts are at a concentration of about 0.1 M to about 1.0 M.
- the wash solution is a solution selected from: (i) a solution comprising sodium benzoate at a concentration of about 0.5 M, and sodium bicarbonate at a concentration of about 50 mM, having a pH of about 10.0; (ii) a solution comprising sodium benzoate at a concentration of about 0.5 M, benzyl alcohol at a concentration of about 2%, arginine at a concentration of about 0.5 M, and sodium phosphate at a concentration of about 50mM, having a pH of about 9.0; (iii) a solution comprising sodium benzoate at a concentration of about 0.5 M and benzyl alcohol at a concentration of about 2% (v/v), having a pH of about 7.0; (iv) a solution comprising sodium benzoate at a concentration of about 0.5 M, benzyl alcohol at a concentration of about 2% (v/v), and sodium chloride at a concentration of about
- the method further comprises a step of washing the matrix with a first solution prior to washing the matrix with the wash solution as described above.
- the first solution comprises a buffer selected from a phosphate buffer, a tris buffer, an acetate buffer, a carbonate buffer, a citrate buffer, and any combinations thereof.
- the first solution comprises the buffer at a concentration of about 10 mM to about 100 mM or about 10 mM to about 500 mM.
- the first solution is a phosphate buffer.
- the method further comprises a step of washing the matrix with a second solution after washing the matrix with the wash solution as described above.
- the second solution comprises a buffer selected from a phosphate buffer, a tris buffer, an acetate buffer, a carbonate buffer, a citrate buffer, and any combinations thereof.
- the second solution comprises the buffer at a concentration of about 10 mM to about 100 mM or about 10 mM to about 500 mM.
- the second solution has a pH of about 5.0 to about 7.0.
- the second solution comprises substantially low salt or no salt.
- the method further comprises a step of contacting the Protein A
- the method further comprises the step of collecting an eluate comprising the polypeptide comprising the Fc region. In some embodiments, the method further comprises a step of filtering the eluate via depth filtration. In some embodiments, the eluate comprises less than about 500 parts per million (ppm) of the one or more impurities.
- the one or more impurities are host cell proteins (HCPs).
- HCPs host cell proteins
- the one or more HCPs are selected from phospholipases (e.g. Putative Phospholipase B-like 2), clusterin, serine proteases, elongation factors, and any combinations thereof.
- the host cell is a mammalian host cell. In some embodiments, the host cell is a Chinese hamster ovary (CHO) cell.
- the Fc region is a human Fc region.
- the human Fc region comprises a human IgGl, IgG2, or IgG4 Fc region.
- the Fc region is a mouse Fc region.
- the mouse Fc region comprises a mouse IgGl, IgG2, or IgG3 Fc region.
- the polypeptide comprising the Fc region is an antibody.
- the antibody is a human antibody, a humanized antibody, or a chimeric antibody.
- the antibody is a monoclonal antibody.
- the antibody is a bispecific antibody or a trispecific antibody.
- any one of the methods above further comprises, before contacting the Protein A chromatography matrix with a sample comprising (i) the polypeptide comprising the Fc region and (ii) one or more impurities, adjusting a harvest comprising the polypeptide comprising the Fc region to achieve a final concentration of a benzoate salt of between about 0.1 M and about 0.5 M and a pH between about 7.0 and about 9.0, e.g., to produce the sample comprising (i) the polypeptide comprising the Fc region, and (ii) one or more impurities.
- the benzoate salt is a benzoate alkali salt.
- the benzoate salt is sodium benzoate.
- the final concentration of the benzoate salt in the harvest is between about 0.4M and about 0.5M.
- the pH of the harvest following adjustment is between about 7.0 and about 8.0. In some embodiments, the pH of the harvest following adjustment is between about 8.0 and about 9.0.
- the harvest is generated from a culture comprising a host cell engineered to express the polypeptide.
- the host cell is a eukaryotic host cell. In some embodiments, the eukaryotic host cell is a Chinese Hamster Ovary (CHO) cell.
- the harvest is clarified prior to the adjusting. In some embodiments, the harvest is clarified following the adjusting.
- a method of purifying a polypeptide comprising an Fc region comprising the steps of: (A) adjusting a harvest comprising the polypeptide comprising the Fc region to achieve a final concentration of a benzoate salt of about 0.1M and about 0.5M and a pH between about 7.0 and about 9.0, e.g ., to produce a sample comprising (i) the polypeptide comprising the Fc region, and (ii) one or more impurities; and (B) contacting the sample with at least one chromatography matrix.
- the at least one chromatography matrix comprises an affinity chromatography matrix.
- the affinity chromatography matrix is a Protein A
- the method further comprises a step of contacting the at least one chromatography matrix with at least one wash solution. In some embodiments, the method further comprises a step of contacting the at least one chromatography matrix with an elution solution. In some embodiments, the method further comprises the step of collecting an eluate comprising the polypeptide comprising the Fc region. In some embodiments, the method further comprises a step of filtering the eluate via depth filtration. In some embodiments, the eluate comprises less than about 500 parts per million (ppm) of the one or more impurities.
- the benzoate salt is a benzoate alkali salt. In some embodiments, the benzoate salt is sodium benzoate. In some embodiments, the final concentration of the benzoate salt in the harvest is between about 0.4M and about 0.5M. In some embodiments, the pH of the harvest following adjustment is between about 7.0 and about 8.0. In some embodiments, the pH of the harvest following adjustment is between about 8.0 and about 9.0. In some embodiments, the harvest is generated from a culture comprising a host cell engineered to express the polypeptide. In some embodiments, the host cell is a eukaryotic host cell. In some embodiments, the eukaryotic host cell is a Chinese Hamster Ovary (CHO) cell.
- CHO Chinese Hamster Ovary
- the harvest is clarified prior to the adjusting. In some embodiments, the harvest is clarified following the adjusting. In some embodiments, the method results in the polypeptide comprising the Fc region being purified away from the one or more impurities to a higher degree than a corresponding method lacking the step of adjusting the harvest comprising the polypeptide comprising the Fc region to produce the sample.
- the one or more impurities are host cell proteins (HCPs). In some embodiments, the one or more HCPs are selected from the group consisting of phospholipases, clusterin, serine proteases, elongation factors, and any combinations thereof. In some embodiments, the HCP is Putative Phospholipase B-like 2 (PLBL2).
- the Fc region is a human Fc region. In some embodiments, the human Fc region comprises a human IgGl, IgG2, or IgG4 Fc region. In some
- the Fc region is a mouse Fc region.
- the mouse Fc region comprises a mouse IgGl, IgG2, or IgG3 Fc region.
- the polypeptide comprising the Fc region is an antibody.
- the antibody is a human antibody, a humanized antibody, or a chimeric antibody.
- the antibody is a monoclonal antibody.
- the antibody is a bispecific antibody or a trispecific antibody.
- FIG. 1 shows the concentration of Chinese hamster ovary (CHO) host cell protein (HCP) impurities in antibody samples eluted from protein A columns after being washed with the indicated control or test wash solutions.
- CHO Chinese hamster ovary
- HCP host cell protein
- FIGS. 2A-B show the concentrations of a specific HCP (HCP-A) in antibody samples eluted from protein A columns.
- FIG. 2A shows the concentration of HCP-A in antibody samples eluted from protein A columns after being washed with 2% benzyl alcohol ⁇ 0.5M sodium benzoate and/or 0.5M arginine in comparison to a control wash, as assessed by ELISA.
- FIG. 2B shows the concentration of HCP-A in antibody samples eluted from protein A columns after being washed with various wash solutions at pH of 9.0 or 10.0 in comparison to a control wash, as assessed by ELISA.
- FIG. 3 shows the concentration of HCP-A in antibody samples eluted from protein A columns after being washed with the indicated wash solutions containing additional test compounds, as assessed by ELISA.
- FIGS. 4A-B show the concentrations of generic HCP and PLBL2 in antibody samples eluted from protein A columns.
- FIG. 4A shows the concentration of generic HCP in antibody samples eluted from protein A columns after being washed with 0.5 M Arginine, 0.5 M Sodium Benzoate, or 4% Benzyl Alcohol in comparison to a process control wash, as assessed by ELISA.
- FIG. 4B shows the concentration of generic PLBL2 in antibody samples eluted from protein A columns after being washed with 0.5 M Arginine, 0.5 M Sodium Benzoate, or 4% Benzyl Alcohol in comparison to a process control wash, as assessed by ELISA.
- FIG. 5 shows the improvement in visual clarity of antibody samples eluted from protein A columns washed with an intermediate wash comprising 2% Benzyl Alcohol and 0.5 M Sodium Benzoate.
- FIGS. 6A-B show the decrease in off-column yield and PLBL2 removal when loading protein A columns beyond 40 g/L.
- FIG. 6A shows the percentage in off-column yield decreases linearly from 93.1% to 78.1% as the loading density of protein A columns increases from 40 g/L to 60 g/L.
- FIG. 6B shows the level of PLBL2 washed out of the protein A column decreases from 32.1 ppm to 17 ppm as the loading density of protein A columns increases from 40 g/L to 60 g/L.
- FIG. 7 shows that harvest adjustment to 0.5 M sodium benzoate and pH 7.2 or harvest adjustment to 0.5 M sodium benzoate and pH 9 prior to protein A purification led to improved removal of PLBL2 and HCP impurities.
- Harvest adjustment to 0.5 M sodium benzoate at pH 9.0 showed the lowest level of PLBL2 and HCP impurities and demonstrated a log greater of PLBL2 clearance relative to a pH adjustment alone.
- FIG. 8 shows the relationship between PLBL2 content and sodium benzoate concentration is approximately sigmoidal. Diminished gains in clearance of PLBL2 were observed for concentrations above 0.4 M sodium benzoate. DETAILED DESCRIPTION
- Described herein are methods of reducing the number of impurities (e.g ., host cell protein impurities) co-purified during protein A-based isolation of Fc-region containing proteins.
- the methods of the present disclosure apply an intermediate wash step using a novel wash solution containing a benzoate salt and/or benzyl alcohol that has been shown to significantly reduce the levels of host cell protein impurities in the eluates collected during protein A affinity chromatography ( See Examples 1 and 2).
- additives e.g., benzenesulfonate, caprylic acid, hexylene glycol, creatine, and/or arginine
- this novel wash solution further improves the clearance of impurities from a protein eluate containing an Fc-region containing protein after capture and elution from a protein A matrix.
- phrase“and/or” as used herein a phrase such as“A and/or B” is intended to include both A and B; A or B; A (alone); and B (alone).
- phrase“and/or” as used herein a phrase such as“A, B, and/or C” is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C;
- polypeptide or "protein” are used interchangeably herein to refer to polymers of amino acids of any length.
- the polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids.
- the terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component or toxin.
- polypeptides containing one or more analogs of an amino acid including, for example, unnatural amino acids, etc.
- antibody is used herein in the broadest sense, and specifically includes monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g ., bispecific antibodies, trispecific antibodies, etc.), antibody fragments, or synthetic polypeptides carrying one or more CDR or CDR-derived sequences so long as the polypeptides exhibit the desired activity.
- Antibodies (Abs) and immunoglobulins (Igs) are glycoproteins having the same structural characteristics.
- antibodies are considered Igs with a defined or recognized specificity.
- immunoglobulins include both antibodies and other antibody -like molecules which lack target specificity.
- the antibodies of the present disclosure may be of any class (e.g., IgG, IgE, IgM, IgD, IgA, etc.), or subclass (e.g., IgGl, IgG2, IgG2a, gG3, IgG4, IgAl, IgA2, etc.).
- The“type” and“class” and “subtype” and“subclass” are used interchangeably herein.
- antibodies and immunoglobulins are usually heterotetrameric glycoproteins of about 150,000 Daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each heavy chain has at one end a variable domain (VH) followed by a number of constant domains. Each light chain has a variable domain (VL) at one end, and a constant domain at the other end.
- Antibodies described herein may be human antibodies, humanized antibodies, non-human animal (e.g, mouse, rat, hamster, rabbit, camelid, etc.) antibodies, or chimeric antibodies.
- variable domains may refer to certain portions of the pertinent molecule which differ extensively in sequence between and among antibodies, and are used in specific recognition and binding or a particular antibody for its particular target. However, the variability is not evenly distributed through the variable domains of antibodies. The variability is concentrated in three segments called complementarity determining regions (CDRs) also known as hypervariable regions, both in the light chain and heavy chain variable domains. The more highly conserved portions of variable domains are called the framework (FR) regions or sequences.
- CDRs complementarity determining regions
- FR framework
- variable domains of native heavy and light chains each comprise four FR regions, largely adopting a b-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the b-sheet structure.
- the CDRs in each chain are held together often in proximity by the FR regions and, with the CDR2 from the other chain, contribute to the formation of the target (epitope or determinant) binding site of antibodies (see Rabat el al. Sequences of Proteins of Immunological Interest, National Institute of Health, Bethesda, MD (1987)).
- numbering of immunoglobulin amino acid residues is done according to the immunoglobulin amino acid residue numbering system of Rabat et al ., unless otherwise indicated.
- One CDR can carry the ability to bind specifically to the cognate epitope.
- the term“hinge” or“hinge region” as used herein, may refer to the flexible polypeptide comprising the amino acid between the first and second constant domains of an antibody.
- bispecific antibodies may refer to molecules which combine the antigen binding sites of two antibodies within a single molecule. Thus, a bi specific antibody is able to bind two different antigens simultaneously.
- the term“monoclonal antibody” used herein may refer to an antibody obtained from a population of substantially homogenous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts.
- Monoclonal antibodies herein specifically include “chimeric” antibodies in which a portion of the heavy and/or light chains is identical or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, with the remained of the chain(s) identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they retain the desired activity.
- multivalent antibody or“polyvalent antibody” as used herein may refer to an antibody comprising two or more antigen binding sites, thus being able to bind two or more antigens, which may have the same or a different structure, simultaneously.
- bivalent means that the antibody comprises two antigen binding sites.
- tetravalent means that the antibody comprises four antigen binding sites.
- antigen binding site may refer to the portion of the antibody which comprises the area which specifically binds to and is complementary to part or all of an antigen. Where an antigen is large, an antibody may only bind to a particular part of the antigen, which part is termed an epitope.
- An antigen binding domain may be provided by one or more antibody variable domains, and may be made of the association of an antibody light chain variable domain (VL) and an antibody heavy chain variable domain (VH).
- “Humanized” forms of non-human (e.g murine) antibodies are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof which contain sequences derived from non-human immunoglobulin, as compared to a human antibody.
- a humanized antibody will comprise substantially all of one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin template sequence.
- the humanized antibody may also comprise at least a portion of an immunoglobulin constant region, typically that of the human immunoglobulin template chosen. In general, the goal is to have an antibody molecule that is minimally immunogenic in a human.
- one or more amino acids in one or more CDRs can also be changed to one that is less immunogenic to a human host, without substantially minimizing the specific binding function of the one or more CDRs to the target.
- the FR can be non-human but those amino acids most immunogenic are replaced with ones less immunogenic.
- CDR grafting is not the only way to obtain a humanized antibody. For example, modifying jus the CDR regions may be insufficient as it is not uncommon for framework residues to have a role in determining the three-dimensional structure of the CDR loops and the overall affinity of the antibody for its ligand.
- any means can be practiced so that the non-human parent antibody molecules is modified to be one that is less immunogenic to a human, and global sequence identity with a human antibody is not always a necessity.
- the term“impurity” may refer to any foreign or undesirable molecule that is present in a solution (such as a sample comprising a polypeptide comprising an Fc region).
- An impurity may be a biological (molecule) (e.g ., a macromolecule) such as DNA, RNA, or protein that is also present in a sample containing a protein of interest.
- Impurities may include undesirable protein variants (e.g., aggregated proteins, misfolded proteins, underdisulfide- bonded proteins, fragments, etc.), other proteins from host cells, components from cell culture medium, molecules that are part of an absorbent used for affinity chromatography (e.g, protein A), endotoxins, nucleic acids, viruses, etc.
- Certain aspects of the present disclosure relate to a method of purifying a polypeptide comprising an Fc region (e.g, an antibody) via protein A chromatography.
- the method comprises the steps of: contacting a protein A
- chromatography matrix or resin with a sample comprising (1) a polypeptide comprising an Fc region (e.g, an antibody) and (2) one or more impurities (e.g, host cell impurities) under a condition that the polypeptide comprising the Fc region (e.g, the antibody) binds to protein A; and washing the matrix with a wash solution comprising a benzoate salt and/or benzyl alcohol.
- the wash solution comprises the benzoate salt at a
- the wash solution comprises the benzyl alcohol at a concentration of about 0.5% to about 4% volume/volume (v/v). In some embodiments, the wash solution has a pH of about 4.0 to about 10.0. In some embodiments, the wash solution comprises one or more additives (e.g, one or more of benzenesulfonate, caprylic acid, hexylene glycol, a non-buffering salt (such as sodium chloride), creatine, and/or arginine). In some embodiments, the wash solution further comprises a buffering agent.
- additives e.g, one or more of benzenesulfonate, caprylic acid, hexylene glycol, a non-buffering salt (such as sodium chloride), creatine, and/or arginine.
- the wash solution further comprises a buffering agent.
- a harvest that comprises the polypeptide comprising an Fc region is adjusted to achieve a final concentration of a benzoate salt of between about 0.1 M and 0.5 M and a pH between about 7 and about 9 to produce the sample comprising (1) a polypeptide comprising an Fc region (e.g, an antibody) and (2) one or more impurities (e.g, host cell impurities).
- a polypeptide comprising an Fc region e.g, an antibody
- impurities e.g, host cell impurities
- Certain aspects of the present disclosure relate to methods of purifying a polypeptide comprising an Fc region (e.g. , an antibody) via protein A chromatography.
- the method comprises a step of: contacting a protein A chromatography matrix or resin with a sample comprising (1) a polypeptide comprising an Fc region (e.g, an antibody) and (2) one or more impurities (e.g, host cell impurities) under a condition that the polypeptide comprising the Fc region (e.g, the antibody) binds to protein A.
- the present disclosure relates to methods of purifying a polypeptide comprising an Fc region (e.g, an antibody, an immunoadhesin, a fusion protein, etc.) from a sample (e.g, a cell lysate sample, a cell culture supernatant sample, etc.).
- a sample e.g, a cell lysate sample, a cell culture supernatant sample, etc.
- the sample is a cell culture supernatant (e.g, a supernatant from cells, such as CHO cells, engineered to produce and secrete the polypeptide), or is derived from a cell culture supernatant (e.g, a partially purified cell culture supernatant sample).
- the polypeptide comprising an Fc region is a secreted polypeptide.
- the Fc region is the C-terminal region of an immunoglobulin heavy chain, and may include native-sequence Fc regions and variant Fc regions.
- the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy-chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof (the numbering of the residues in the Fc region is that of the EU index as in Kabat).
- the Fc region of an immunoglobulin generally comprises two constant domains, CH2 and CH3, and optionally comprises a CH4 domain.
- the Fc region is an Fc region obtained from any suitable immunoglobulin, such as IgGl lgG2, lgG3, or lgG4 subtypes, IgA, IgE, IgD or IgM.
- the polypeptide comprises an Fc region having the amino acid sequence of a human Fc region, a non-human animal Fc region (e.g, a mouse, rat, rabbit, hamster, etc.), or any combinations thereof.
- the Fc region is a mouse Fc region.
- the mouse Fc region comprises a mouse IgGl, IgG2, or IgG3 Fc region.
- the Fc region is a human Fc region.
- the human Fc region comprises a human IgGl, IgG2, and/or IgG4 Fc region.
- the polypeptide comprising an Fc region is an antibody.
- antibody is used herein in the broadest sense, and specifically covers monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multivalent antibodies (e.g ., bivalent, trivalent, tetravalent, etc.), and multispecific antibodies (e.g., bispecific, trispecific, etc.).
- Antibodies may be from any origin, including, for example, humans, non-human primates, rodents (e.g, mouse, rat, hamster, etc.), rabbits, camelids, sharks, and/or recombinantly produced.
- the antibody is a human antibody, a humanized antibody, and/or a chimeric antibody.
- the antibody is a monoclonal antibody.
- the antibody is a multispecific and/or multivalent antibody.
- the antibody is a bispecific antibody or a trispecific antibody.
- the sample e.g, a cell lysate sample, a cell culture supernatant sample, etc.
- the polypeptide comprising an Fc region further comprises one of more impurities.
- the one or more impurities are present in the sample due to the process employed for producing the polypeptide comprising the Fc region (e.g, the process of producing a secreted antibody).
- the one or more impurities are one or more impurities derived from a host cell (e.g, one or more host cell proteins, one or more host cell nucleic acids, one or more host cell lipids, etc.).
- the host cell may be any host cell known in the art suitable for the production of a polypeptide comprising an Fc region, including, for example, prokaryotic cells (such as E. colt cells, A. niger cells, etc.), eukaryotic cells (such as yeast cells, plant cells, insect cells (e.g, Sl cells), and/or mammalian (mouse, rat, hamster, rabbit, human, non-human primate, etc.) cells (e.g, hybridomas, CHO cells, 293T cells, PER.C6 cells, NSO cells, etc.).
- the one or more impurities are one or more host cell proteins (HCPs).
- an HCP refers to a non-product protein produced by a host cell during cell culture or
- the one or more impurities are one or more (e.g, one or more, two or more, three or more, four or more, etc.) host cell proteins (HCPs) selected from phospholipases, clusterin, serine proteases, elongation factors, and/or any combinations thereof.
- the host cell is a CHO cell.
- the one or more impurities are one or more CHO cell HCPs.
- the one or more CHO cell HCPs are one or more of phospholipases, clusterin, serine proteases, elongation factors, and/or any combinations thereof.
- the present disclosure relates to methods of purifying a polypeptide comprising an Fc region away from one or more impurities in a sample via protein A chromatography.
- the sample is contacted with a protein A matrix or resin.
- the sample is contacted with the protein A matrix or resin under conditions suitable for the polypeptide comprising the Fc region in the sample to bind to protein A.
- Methods and suitable conditions for contacting and binding an Fc-region containing polypeptide to a protein A matrix or resin are readily understood by one of ordinary skill in the art (e.g methods as described in the manufacturer’s protocol of a commercially available protein A matrix or resin).
- Any suitable protein A matrix or resin known in the art may be used in the methods of the present disclosure, including, for example: MabSelect, MabSelect Xtra, MabSelect Sure, MabSelect Sure LX Protein A, MabSelect pcc, MabSelect PrismA, rProtein A Sepharose CL-4B, and nProtein A Sepharose 4 FF (GE Healthcare); EshmunoA, ProSep A, ProSep-vA High Capacity, ProSep-vA LTltra, and ProSep-vA LTltraPlus (Millipore); Poros A and Mabcapture A (Poros); IPA-300, IPA- 400, and IPA-500 (RepliGen Corp.); Affigel protein A and Affiprep protein A (Bio-Rad); MABsorbent A1PP and MABsorbent A2P (Affinity Chromatography Ltd.); Protein A Ceramic Hyper D
- the protein A matrix or resin is used in a column chromatography format.
- one or more parameters of the protein A matrix or resin (such as pH, ionic strength, temperature, the addition of other substances) is adjusted prior to contacting the protein A matrix or resin with a sample.
- the protein A matrix or resin is flushed, washed, equilibrated, stripped, and/or sanitized prior to and/or after contacting the protein A matrix or resin with the sample.
- the protein A matrix or resin is equilibrated and/or washed prior to contacting the protein A matrix or resin with the sample. Any suitable equilibration and/or wash buffer known in the art may be used.
- the protein A matrix or resin is sanitized, stripped, and/or regenerated between uses.
- Certain aspects of the present disclosure relate to methods of purifying a polypeptide comprising an Fc region via protein A chromatography by washing a protein A matrix or resin bound to the polypeptide comprising an Fc region (e.g, an antibody) with a wash solution comprising a benzoate salt and/or benzyl alcohol.
- the method comprises a step of: contacting a protein A chromatography matrix or resin with a sample comprising (1) a polypeptide comprising an Fc region (e.g ., an antibody) and (2) one or more impurities (e.g., host cell impurities) under a condition that the polypeptide comprising the Fc region (e.g, the antibody) binds to protein A; and washing the matrix or resin with a wash solution comprising a benzoate salt at a concentration of about 0.1 M to about 1.0 M and/or benzyl alcohol at a concentration of about 0.5% to about 4%
- the wash solution comprises a benzoate salt.
- the wash solution comprises benzyl alcohol.
- the wash solution comprises a benzoate salt and benzyl alcohol.
- the present disclosure relates to a wash solution comprising a benzoate salt and/or benzoic acid (e.g, pH adjusted).
- a benzoate salt e.g, an alkali salt
- benzoic acid e.g, pH adjusted
- Any suitable source or form of a benzoate salt (e.g, an alkali salt) and/or benzoic acid known in the art may be used in the wash solutions of the present disclosure, including, for example, sodium benzoate, potassium benzoate, lithium benzoate, calcium benzoate, magnesium benzoate, beryllium benzoate, barium benzoate, strontium benzoate, rubidium benzoate, cesium benzoate, and/or any combinations thereof.
- the benzoate salt is a benzoate alkali salt.
- the benzoate salt is sodium benzoate or potassium benzoate.
- the benzoate salt is sodium benzoate.
- the benzoate salt (e.g, sodium benzoate) and/or benzoic acid is present in the wash solution at a concentration of about 0.1 M to about 1.0 M.
- the benzoate salt (e.g, sodium benzoate) and/or benzoic acid may be present in the wash solution at a concentration of about 0.1 M to about 1.0 M, about 0.1 M to about 0.9 M, about 0.1 M to about 0.8 M, about 0.1 M to about 0.7 M, about 0.1 M to about 0.6 M, about 0.1 M to about 0.5 M, about 0.1 M to about 0.4 M, about 0.1 M to about 0.3 M, about 0.1 M to about 0.2 M, about 0.2 M to about 1.0 M, about 0.2 M to about 0.9 M, about 0.2 M to about 0.8 M, about 0.2 M to about 0.7 M, about 0.2 M to about 0.6 M, about 0.2 M to about 0.5 M, about 0.2 M to about 0.4 M, about 0.2 M to about 0.2 M to about 1.0 M,
- the benzoate salt (e.g ., sodium benzoate) and/or benzoic acid is present in the wash solution at a concentration of about 0.1 M to about 0.5 M. In some embodiments, the benzoate salt (e.g., sodium benzoate) and or benzoic acid is present in the wash solution at a concentration of about 0.1 M to about 0.3 M.
- the benzoate salt (e.g, sodium benzoate) and/or benzoic acid is present in the wash solution at a concentration of any of about 0.1 M, 0.15 M, 0.2 M, 0.25 M, 0.3 M, 0.35 M, 0.4 M, 0.45 M, 0.5 M, 0.55 M, 0.6 M, 0.65 M, 0.7 M, 0.75 M, 0.8 M, 0.85 M, 0.9 M, 0.95 M, or 1.0 M.
- the benzoate salt (e.g., sodium benzoate) and/or benzoic acid is present in the wash solution at a concentration of about 0.5 M.
- the benzoate salt (e.g, sodium benzoate) and/or benzoic acid is present in the wash solution at a concentration of about 0.1 M or less than about 0.1 M, about 0.3 M or less than about 0.3 M, about 0.5 M or less than about 0.5 M, about 0.75 M or less than about 0.75 M, or about 1.0 M or less than about 1.0 M. In some embodiments, the benzoate salt (e.g, sodium benzoate) and/or benzoic acid is present in the wash solution at a concentration of about 0.5 M or less than about 0.5 M.
- the present disclosure relates to a wash solution comprising benzyl alcohol.
- benzyl alcohol Any suitable source or form of benzyl alcohol known in the art may be used in the wash solutions of the present disclosure.
- the benzyl alcohol is present in the wash solution at a concentration of about 0.5% to about 4.0% volume/volume (v/v).
- the benzyl alcohol may be present in the wash solution at a concentration of about 0.5% to about 4%, about 1% to about 4%, about 1.5% to about 4%, about 2% to about 4%, about 2.5% to about 4%, about 3% to about 4%, about 3.5% to about 4%, about 0.5% to about 3.5%, about 1% to about 3.5%, about 1.5% to about 3.5%, about 2% to about 3.5%, about 2.5% to about 3.5%, about 3% to about 3.5%, about 0.5% to about 3%, about 1% to about 3%, about 1.5% to about 3%, about 2% to about 3%, about 2.5% to about 3%, about 0.5% to about 2.5%, about 1% to about 2.5%, about 1.5% to about 2.5%, about 2% to about 2.5%, about 0.5% to about 2%, about 1% to about 2%, about 1%, about 0.5% to about
- the benzyl alcohol is present in the wash solution at a concentration of about 1% to about 4% volume/volume (v/v). In some embodiments, the benzyl alcohol is present in the wash solution at a concentration of about 1% to about 2% volume/volume (v/v).
- the benzyl alcohol is present in the wash solution at a concentration of any of about 0.5%, 0.75%, 1%, 1.25%, 1.5%, 1.75%, 2%, 2.25%, 2.5%, 2.75%, 3%, 3.25%, 3.5%, 3.75%, or about 4% (v/v). In some embodiments, the benzyl alcohol is present in the wash solution at a concentration of about 2% (v/v). In some embodiments, the benzyl alcohol is present in the wash solution at a concentration of about 1% or less than about 1%, about 2% or less than about 2%, about 3% or less than about 3%, or about 4% or less than about 4%.
- the benzyl alcohol is present in the wash solution at a concentration of about 4% or less than about 4% (v/v). In some embodiments, the benzyl alcohol is present in the wash solution at a concentration of about 4% or less than about 2% (v/v).
- a wash solution of the present disclosure further comprises one or more (e.g ., one or more, two or more, three or more, four or more, or all five) of the following additives: benzenesulfonate, caprylic acid, hexylene glycol, a non- buffering salt, and/or creatine at any of the concentrations described herein.
- the wash solution comprising the one or more additives has a pH of about 4.0 to about 10.0.
- the inclusion of the one or more additives in the wash solution further improves the purification of a polypeptide comprising an Fc region away from one or more impurities (e.g., host cell impurities) by the methods described herein.
- the wash solution comprises a benzoate salt and/or benzyl alcohol and one of benzenesulfonate, caprylic acid, hexylene glycol, a non-buffering salt, and/or creatine at a pH of about 4.0 to about 10.0.
- the wash solution may comprise: benzoate salt and/or benzyl alcohol and benzenesulfonate; benzoate salt and/or benzyl alcohol and caprylic acid; benzoate salt and/or benzyl alcohol and hexylene glycol; benzoate salt and/or benzyl alcohol and a non-buffering salt; or benzoate salt and/or benzyl alcohol and creatine, at a pH of about 4.0 to about 10.0.
- the wash solution comprises a benzoate salt and/or benzyl alcohol and two of benzenesulfonate, caprylic acid, hexylene glycol, a non-buffering salt, and/or creatine at a pH of about 4.0 to about 10 0
- the wash solution may comprise: benzoate salt and/or benzyl alcohol, benzenesulfonate, and caprylic acid; benzoate salt and/or benzyl alcohol, benzenesulfonate, and hexylene glycol; benzoate salt and/or benzyl alcohol, benzenesulfonate, and a non-buffering salt; benzoate salt and/or benzyl alcohol, benzenesulfonate, and creatine; benzoate salt and/or benzyl alcohol, caprylic acid, and hexylene glycol; benzoate salt and/or benzyl alcohol, caprylic acid, and hexylene glycol;
- the wash solution comprises a benzoate salt and/or benzyl alcohol and three of benzenesulfonate, caprylic acid, hexylene glycol, a non-buffering salt, and/or creatine at a pH of about 4.0 to about 10 0
- the wash solution may comprise: benzoate salt and/or benzyl alcohol, benzenesulfonate, caprylic acid, and hexylene glycol; benzoate salt and/or benzyl alcohol, benzenesulfonate, caprylic acid, and a non- buffering salt; benzoate salt and/or benzyl alcohol, benzenesulfonate, caprylic acid, and creatine; benzoate salt and/or benzyl alcohol, benzenesulfonate, hexylene glycol, and a non- buffering salt; benzoate salt and/or benzyl alcohol, benzenesulfonate, hexylene glyco
- the wash solution comprises a benzoate salt and/or benzyl alcohol and four of benzenesulfonate, caprylic acid, hexylene glycol, a non-buffering salt, and/or creatine at a pH of about 4.0 to about 10 0
- the wash solution may comprise: benzoate salt and/or benzyl alcohol, benzenesulfonate, caprylic acid, hexylene glycol, and a non-buffering salt; benzoate salt and/or benzyl alcohol, benzenesulfonate, caprylic acid, hexylene glycol, and creatine; benzoate salt and/or benzyl alcohol, benzenesulfonate, caprylic acid, a non-buffering salt, and creatine; benzoate salt and/or benzyl alcohol, benzenesulfonate, hexylene glycol, a non-buffering salt, and creatine; benzoate salt
- the wash solution comprises a benzoate salt and/or benzyl alcohol and all five of benzenesulfonate, caprylic acid, hexylene glycol, a non- buffering salt, and creatine at a pH of about 4.0 to about 10.0.
- the present disclosure relates to a wash solution comprising benzenesulfonate.
- benzenesulfonate Any suitable form or source of benzenesulfonate known in the art may be used in the wash solutions of the present disclosure, including, for example, a benzenesulfonate salt (e.g ., an alkali salt) such as sodium benzenesulfonate or potassium benzenesulfonate, benzenesulfonic acid, and/or any combinations thereof.
- the benzenesulfonate is sodium benzenesulfonate.
- the benzenesulfonate (e.g., sodium benzenesulfonate) is present in the wash solution at a concentration of about 0.1 M to about 0.5 M.
- the sodium benzenesulfonate may be present in the wash solution at a concentration of about 0.1 M to about 0.5 M, about 0.1 M to about 0.4 M, about 0.1 M to about 0.3 M, about 0.1 M to about 0.2 M, about 0.2 M to about 0.5 M, about 0.2 M to about 0.4 M, about 0.2 M to about 0.3 M, about 0.3 M to about 0.5 M, about 0.3 M to about 0.4 M, or about 0.4 M to about 0.5 M.
- the sodium benzenesulfonate is present in the wash solution at a concentration of about 0. 1 M to about 0.3 M.
- the sodium benzenesulfonate is present in the wash solution at a concentration of any of about 0.1 M, 0.15 M, 0.2 M, 0.25 M, 0.3 M, 0.35 M, 0.4 M, 0.45 M, or 0.5 M. In some embodiments, the sodium benzenesulfonate is present in the wash solution at a concentration of about 0.5 M. In some embodiments, the sodium benzenesulfonate is present in the wash solution at a concentration of about 0.1 M or less than about 0.1 M, about 0.3 M or less than about 0.3 M, or about 0.5 M or less than about 0.5 M.
- the sodium benzenesulfonate is present in the wash solution at a concentration of about 0.5 M or less than about 0.5 M.
- the present disclosure relates to a wash solution comprising caprylic acid. Any suitable form or source of caprylic acid known in the art may be used in the wash solutions of the present disclosure.
- the caprylic acid is present in the wash solution at a concentration of about 1 mM to about 50 mM.
- the caprylic acid may be present in the wash solution at a concentration of about 1 mM to about 50 mM, about 10 mM to about 50 mM, about 20 mM to about 50 mM, about 30 mM to about 50 mM, about 40 mM to about 50 mM, about 1 mM to about 40 mM, about 10 mM to about 40 mM, about 20 mM to about 40 mM, about 30 mM to about 40 mM, about 1 mM to about 30 mM, about 10 mM to about 30 mM, about 20 mM to about 30 mM, about 1 mM to about 20 mM, about 10 mM to about 20 mM, or about 1 mM to about 10 mM.
- the caprylic acid is present in the wash solution at a concentration of about 1 mM to about 50
- the caprylic acid is present in the wash solution at a concentration of any of about 1 mM, 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, or 50 mM. In some embodiments, the caprylic acid is present in the wash solution at a concentration of about 50 mM. In some embodiments, the caprylic acid is present in the wash solution at a concentration of about 10 mM or less than about 10 mM, about 30 mM or less than about 30 mM, or about 50 mM or less than about 50 mM. In some embodiments, the caprylic acid is present in the wash solution at a concentration of about 50 mM or less than about 50 mM.
- the present disclosure relates to a wash solution comprising hexylene glycol.
- a wash solution comprising hexylene glycol.
- Any suitable form or source of hexylene glycol known in the art may be used in the wash solutions of the present disclosure.
- the hexylene glycol is present in the wash solution at a concentration of about 0.5% to about 10% (v/v).
- the hexylene may be present in the wash solution at a concentration of about 0.5% to about 10%, about 1% to about 10%, about 2% to about 10%, about 4% to about 10%, about 6% to about 10%, about 8% to about 10%, about 9% to about 10%, 0.5% to about 9%, about 1% to about 9%, about 2% to about 9%, about 4% to about 9%, about 6% to about 9%, about 8% to about 9%, about 0.5% to about 8%, about 1% to about 8%, about 2% to about 8%, about 4% to about 8%, about 6% to about 8%, about 0.5% to about 6%, about 1% to about 6%, about 2% to about 6%, about 4% to about 6%, about 0.5% to about 4%, about 1% to about 4%, about 2% to about 4%, about 0.5% to about 4%, about 1% to
- the hexylene glycol is present in the wash solution at a concentration of any of about 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% (v/v). In some embodiments, the hexylene glycol is present in the wash solution at a concentration of about 10% (v/v).
- the hexylene glycol is present in the wash solution at a concentration of about 1% or less than about 1%, about 2% or less than about 2%, about 4% or less than about 4%, about 6% or less than about 6%, about 8% or less than about 8%, or about 10% or less than about 10% (v/v). In some embodiments, the hexylene glycol is present in the wash solution at a concentration of aboutl0% or less than about 10% (v/v).
- the present disclosure relates to a wash solution comprising one or more (e.g ., one or, two or more, three or more, etc.) non-buffering salts.
- a non-buffering salt Any suitable form or source of a non-buffering salt known in the art may be used in the wash solutions of the present disclosure.
- Non-buffering salts may include halogen salts (such as those that comprise Cl or Br), in particular halogen salts comprising alkali metals (such as Na or K) or alkaline earth metals (such as Ca or Mg).
- the non-buffering salt is sodium chloride or potassium chloride.
- the non-buffering salt is sodium chloride.
- the non-buffering salt e.g., sodium chloride
- the non-buffering salt may be present in the wash solution at a concentration of about 0.1 M to about 1.0 M, about 0.1 M to about 0.8 M, about 0.1 M to about 0.6 M, about 0.1 M to about 0.5 M, about 0.1 M to about 0.4 M, about 0.1 M to about 0.2 M, about 0.2 M to about 1.0 M, about 0.2 M to about 0.8 M, about 0.2 M to about 0.6 M, about 0.2 M to about 0.5 M, about 0.2 M to about 0.4 M, about 0.4 M to about 1.0 M, about 0.4 M to about 0.8 M, about 0.4 M to about 0.6 M, about 0.4 M to about 0.5 M, about 0.5 M to about 1.0 M, about 0.4 M to about 0.8 M, about 0.4 M to about 0.6 M, about 0.4 M to about 0.5 M, about 0.5 M to about 1.0 M, about 0.5 M to about 0.8 M, about 0.5 M to about
- the non- buffering salt e.g, sodium chloride
- the non-buffering salt e.g., sodium chloride
- the wash solution at a concentration of about 0.5 M to about 1.0 M.
- the non-buffering salt e.g., sodium chloride
- the non-buffering salt is present in the wash solution at a concentration of any of about 0.1 M, 0.15 M, 0.2 M, 0.25 M, 0.3 M, 0.35 M, 0.4 M, 0.45 M, 0.5 M, 0.55 M, 0.6 M, 0.65 M, 0.7 M, 0.75 M, 0.8 M, 0.85 M, 0.9 M, 0.95 M, or 1.0 M.
- the non-buffering salt e.g, sodium chloride
- the non-buffering salt is present in the wash solution at a concentration of about 0.5 M.
- the non-buffering salt e.g, sodium chloride
- the wash solution at a concentration of about 1.0 M.
- the non-buffering salt e.g, sodium chloride
- the non-buffering salt is present in the wash solution at a concentration of about 0.1 M or less than about 0.1 M, about 0.2 M or less than about 0.2 M, about 0.4 M or less than about 0.4 M, about 0.5 M or less than about 0.5 M, about 0.6 M or less than about 0.6 M, about 0.8 M or less than about 0.8 M, or about 1.0 M or less than about 1.0 M.
- the non-buffering salt e.g, sodium chloride
- the non-buffering salt is present in the wash solution at a concentration of about 0.5 M or less than about 0.5 M.
- the non-buffering salt e.g, sodium chloride
- the wash solution at a concentration of about 1.0 M or less than about 1.0 M.
- the present disclosure relates to a wash solution comprising creatine.
- a wash solution comprising creatine.
- Any suitable form or source of creatine known in the art may be used in the wash solutions of the present disclosure, including, for example, creatine-HCl, creatine esters, creatine pyruvate, creatine phosphate, create alpha-ketoglutarate, creatine citrate, and/or any combinations thereof.
- the creatine is creatine-HCl.
- the creatine is present in the wash solution at a concentration of about 1 mM to about 100 mM.
- the creatine may be present in the wash solution at a concentration of about 1 mM to about 100 mM, about 10 mM to about 100 mM, about 25 mM to about 100 mM, about 50 mM to about 100 mM, about 75 mM to about 100 mM, about 1 mM to about 75 mM, about 10 mM to about 75 mM, about 25 mM to about 75 mM, about 50 mM to about 75 mM, about 1 mM to about 50 mM, about 10 mM to about 50 mM, about 25 mM to about 50 mM, about 1 mM to about 25 mM, about 10 mM to about 25 mM, or about 1 mM to about 10 mM.
- the creatine is present in the wash solution at a concentration of about 10 mM to about 100 mM. In some embodiments, the creatine is present in the wash solution at a concentration of about 10 mM to about 50 mM. In some embodiments, the creatine is present in the wash solution at a concentration of any of about 1 mM, 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, or 100 mM. In some embodiments, the creatine is present in the wash solution at a concentration of about 50 mM.
- the present disclosure relates to a wash solution further comprising arginine and/or an arginine derivative.
- the inclusion of arginine and/or an arginine derivative in the wash solution further improves the purification of a polypeptide comprising an Fc region away from one or more impurities (e.g ., host cell impurities) by the methods described herein.
- arginine and/or an arginine derivative known in the art may be used in the wash solutions of the present disclosure, including, for example, arginine, arginine-HCl, acetyl arginine, agmatine, arginic acid, N-alpha-butyroyl-L-arginine, N-alpha-pyvaloyl arginine, and/or any combinations thereof.
- the arginine and/or arginine derivative may be L-arginine and/or D-arginine, and derivatives thereof.
- the arginine and/or arginine derivative is arginine- HCl.
- the present disclosure relates to the use of arginine and/or an arginine derivative (e.g., arginine-HCl) in a wash solution comprising a benzoate salt and/or benzyl alcohol.
- the wash solution comprises a benzoate salt and arginine and/or an arginine derivative (e.g, arginine-HCl).
- the wash solution comprises benzyl alcohol and arginine and/or an arginine derivative (e.g, arginine-HCl).
- the wash solution comprises a benzoate salt, benzyl alcohol, and arginine and/or an arginine derivative (e.g, arginine-HCl).
- the wash solution further comprises one or more (e.g, one or more, two or more, three or more, four or more, or all five) of benzenesulfonate, caprylic acid, hexylene glycol, a non-buffering salt, and/or creatine at any of the concentrations described herein.
- a wash solution comprising arginine and/or an arginine derivative has a pH of about 4.0 to about 10.0.
- a wash solution comprising arginine and/or an arginine derivative has a pH of about 4.0 to about 6.0.
- a wash solution comprising arginine and/or an arginine derivative has a pH of about 4.0 to about 5.0. In some embodiments, a wash solution comprising arginine and/or an arginine derivative has a pH of about 8.0 to about 10 0 In some embodiments, a wash solution comprising arginine and/or an arginine derivative has a pH of about 8.0 to about 9 0
- the wash solution comprises a benzoate salt and/or benzyl alcohol, arginine and/or an arginine derivative (e.g ., arginine-HCl), and one of benzenesulfonate, caprylic acid, hexylene glycol, a non-buffering salt, and/or creatine.
- arginine and/or an arginine derivative e.g ., arginine-HCl
- the wash solution may comprise: benzoate salt and/or benzyl alcohol, arginine, and benzenesulfonate; benzoate salt and/or benzyl alcohol, arginine, and caprylic acid; benzoate salt and/or benzyl alcohol, arginine, and hexylene glycol; benzoate salt and/or benzyl alcohol, arginine, and a non-buffering salt; or benzoate salt and/or benzyl alcohol, arginine, and creatine.
- the wash solution comprises a benzoate salt and/or benzyl alcohol, arginine and/or an arginine derivative (e.g., arginine-HCl), and two of benzenesulfonate, caprylic acid, hexylene glycol, a non-buffering salt, and/or creatine.
- the wash solution may comprise: benzoate salt and/or benzyl alcohol, arginine, benzenesulfonate, and caprylic acid; benzoate salt and/or benzyl alcohol, arginine, benzenesulfonate, and hexylene glycol; benzoate salt and/or benzyl alcohol, arginine, benzenesulfonate, and a non-buffering salt; benzoate salt and/or benzyl alcohol, arginine, benzenesulfonate, and creatine; benzoate salt and/or benzyl alcohol, arginine, caprylic acid, and hexylene glycol; benzoate salt and/or benzyl alcohol, arginine, caprylic acid, and a non- buffering salt; benzoate salt and/or benzyl alcohol, arginine, caprylic acid, and creatine;
- the wash solution comprises a benzoate salt and/or benzyl alcohol, arginine and/or an arginine derivative (e.g, arginine-HCl), and three of benzenesulfonate, caprylic acid, hexylene glycol, a non-buffering salt, and/or creatine.
- arginine and/or an arginine derivative e.g, arginine-HCl
- the wash solution may comprise: benzoate salt and/or benzyl alcohol, arginine, benzenesulfonate, caprylic acid, and hexylene glycol; benzoate salt and/or benzyl alcohol, arginine, benzenesulfonate, caprylic acid, and a non-buffering salt; benzoate salt and/or benzyl alcohol, arginine, benzenesulfonate, caprylic acid, and creatine; benzoate salt and/or benzyl alcohol, arginine, benzenesulfonate, hexylene glycol, and a non-buffering salt;
- the wash solution comprises a benzoate salt and/or benzyl alcohol, arginine and/or an arginine derivative (e.g ., arginine-HCl), and four of benzenesulfonate, caprylic acid, hexylene glycol, a non-buffering salt, and/or creatine.
- arginine and/or an arginine derivative e.g ., arginine-HCl
- the wash solution may comprise: benzoate salt and/or benzyl alcohol, arginine, benzenesulfonate, caprylic acid, hexylene glycol, and a non-buffering salt; benzoate salt and/or benzyl alcohol, arginine, benzenesulfonate, caprylic acid, hexylene glycol, and creatine; benzoate salt and/or benzyl alcohol, arginine, benzenesulfonate, caprylic acid, a non-buffering salt, and creatine; benzoate salt and/or benzyl alcohol, arginine,
- benzenesulfonate hexylene glycol, a non-buffering salt, and creatine
- benzoate salt and/or benzyl alcohol, arginine, caprylic acid, hexylene glycol, a non-buffering salt, and creatine benzoate salt and/or benzyl alcohol, arginine, caprylic acid, hexylene glycol, a non-buffering salt, and creatine.
- the wash solution comprises a benzoate salt and/or benzyl alcohol, arginine and/or an arginine derivative (e.g., arginine-HCl), and all five of benzenesulfonate, caprylic acid, hexylene glycol, a non-buffering salt, and creatine.
- arginine e.g., arginine-HCl
- the arginine and/or arginine derivative e.g, arginine-
- HCl is present in the wash solution at a concentration of about 0.1 M to about 1.0 M.
- the arginine and/or arginine derivative e.g, arginine-HCl
- the wash solution may be present at a concentration of about 0.1 M to about 1.0 M, about 0.1 M to about 0.9 M, about 0.1 M to about 0.8 M, about 0.1 M to about 0.7 M, about 0.1 M to about 0.6 M, about 0.1 M to about 0.5 M, about 0.1 M to about 0.4 M, about 0.1 M to about 0.3 M, about 0.1 M to about 0.2 M, about 0.2 M to about 1.0 M, about 0.2 M to about 0.9 M, about 0.2 M to about 0.8 M, about 0.2 M to about 0.7 M, about 0.2 M to about 0.6 M, about 0.2 M to about 0.5 M, about 0.2 M to about 0.4 M, about 0.2 M to about 0.3 M, about 0.3 M to about 0.2 M, about 0.2 M to about 1.0 M,
- the arginine and/or arginine derivative e.g ., arginine-HCl
- the arginine and/or arginine derivative is present in the wash solution at a concentration of about 0.1 M to about 0.5 M.
- the arginine and/or arginine derivative is present in the wash solution at a concentration of about 0.1 M to about 0.3 M.
- the arginine and/or arginine derivative e.g, arginine-
- HCl HCl
- the arginine and/or arginine derivative e.g, arginine-HCl
- the arginine and/or arginine derivative (e.g, arginine-HCl) is present in the wash solution at a concentration of about 0.1 M or less than about 0.1 M, about 0.2 M or less than about 0.2 M, about 0.3 M or less than about 0.3 M, about 0.4 M or less than about 0.4 M, about 0.5 M or less than about 0.5 M, about 0.75 M or less than about 0.75 M, or about 1.0 M or less than about 1.0 M.
- the arginine and/or arginine derivative (e.g, arginine-HCl) is present in the wash solution at a concentration of about 0.5 M or less than about 0.5 M.
- the present disclosure relates to a wash solution having a pH of about 4.0 to about 10.0.
- the wash solution may have a pH of about 4.0 to about 10.0, about 5.0 to about 10.0, about 6.0 to about 10.0, about 6.5 to about 10.0, about 7.0 to about 10.0, about 7.5 to about 10.0, about 8.0 to about 10.0, about 9.0 to about 10.0,
- the wash solution has a pH of about 5.0 to about 9.0. In some embodiments, the wash solution has a pH of about 4.0 to about 6.0. In some embodiments, the wash solution has a pH of about 4.0 to about 5.0. In some embodiments, the wash solution has a pH of about 8.0 to about 10.0. In some embodiments, the wash solution has a pH of about 8.0 to about 9.0.
- the wash solution has a pH of any of about 4.0, 4.25,
- the wash solution has a pH of about 4.0. In some embodiments, the wash solution has a pH of about 5.0. In some embodiments, the wash solution has a pH of about 6.0. In some embodiments, the wash solution has a pH of about
- the wash solution has a pH of about 7.0. In some embodiments, the wash solution has a pH of about 7.5. In some embodiments, the wash solution has a pH of about 9.0. In some embodiments, the wash solution has a pH of about 10.0.
- a wash solution of the present disclosure further comprises one or more (e.g ., one or more, two or more, three or more, four or more, five or more, etc.) buffering agents.
- buffering agent known in the art may be used in the wash solutions of the present disclosure, including, for example phosphate, tris
- the buffering agent e.g., phosphate, tris, arginine, acetate, and/or citrate
- the buffering agent is present in the wash solution at a concentration of about 1 mM to about 100 mM or about 1 mM to about 500 mM.
- the buffering agent e.g, phosphate, tris, arginine, acetate, and/or citrate
- the buffering agent may be present in the wash solution at a concentration of about lmM to about 500 mM, 10 mM to about 500 mM, 50 mM to about 500 mM, 100 mM to about 500 mM, 150 mM to about 500 mM, 200 mM to about 500 mM, 250 mM to about 500 mM, 300 mM to about 500 mM, 350 mM to about 500 mM, 400 mM to about 500 mM, 450 mM to about 500 mM, lmM to about 450 mM, lmM to about 400 mM, lmM to about 350 mM, lmM to about 300 mM, lmM to about 250 mM, lmM to about 200 mM, lmM to about 150 mM, 1 mM to
- the buffering agent e.g ., phosphate, tris, arginine, acetate, and/or citrate
- the buffering agent is present in the wash solution at a concentration of about 10 mM to about 50 mM or about 10 mM to about 500mM.
- the buffering agent e.g., phosphate, tris, arginine, acetate, and/or citrate
- the buffering agent is present in the wash solution at a concentration of any of about 1 mM, 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, or 100 mM.
- the buffering agent e.g., phosphate, tris, arginine, acetate, and/or citrate
- the buffering agent e.g, phosphate, tris, arginine, acetate, and/or citrate
- the buffering agent is present in the wash solution at a concentration of any of about 150 mM, 200 mM, 250 mM, 300 mM, 350 mM, 400 mM, 450 mM, or 500 mM.
- the buffering agent e.g, phosphate, tris, arginine, acetate, and/or citrate
- the buffering agent is present in the wash solution at a concentration of about 500 mM.
- the buffering agent e.g, phosphate, tris, arginine, acetate, and/or citrate
- the buffering agent is present in the wash solution at a concentration of about 50 mM.
- the buffering agent e.g, phosphate, tris, arginine, acetate, and/or citrate
- the buffering agent e.g ., phosphate, tris, arginine, acetate, and/or citrate
- the buffering agent is present in the wash solution at a concentration of about 50 mM or less than about 50 mM.
- the buffering agent e.g., phosphate, tris, arginine, acetate, and/or citrate
- the buffering agent is present in the wash solution at a concentration of about 500 mM or less than about 500 mM.
- a wash solution of the present disclosure comprises sodium benzoate and/or benzyl alcohol, and has a pH of about 7.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M and/or benzyl alcohol at a concentration of about 2% (v/v), and has a pH of about 7.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M and benzyl alcohol at a concentration of about 2% (v/v), and has a pH of about 7.0.
- the wash solution further comprises phosphate buffer (e.g, at a concentration of about 50 mM).
- a wash solution of the present disclosure comprises sodium benzoate, benzyl alcohol, and/or sodium chloride, and has a pH of about 7.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M, benzyl alcohol at a concentration of about 2% (v/v), and/or sodium chloride at a concentration of about 0.5 M, and has a pH of about 7.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M, benzyl alcohol at a concentration of about 2% (v/v), and sodium chloride at a concentration of about 0.5 M, and has a pH of about 7.0.
- the wash solution further comprises phosphate buffer (e.g, at a concentration of about 50 mM).
- a wash solution of the present disclosure comprises sodium benzoate, benzyl alcohol, arginine, and/or sodium chloride, and has a pH of about 7.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M, benzyl alcohol at a concentration of about 2% (v/v), arginine at a
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M, benzyl alcohol at a concentration of about 2% (v/v), arginine at a concentration of about 0.5 M, and sodium chloride at a concentration of about 0.5 M, and has a pH of about 7.0.
- the wash solution further comprises phosphate buffer ( e.g at a concentration of about 50 mM).
- a wash solution of the present disclosure comprises sodium benzoate, benzyl alcohol, phosphate buffer, and/or arginine, and has a pH of about 9.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M, benzyl alcohol at a concentration of about 2% (v/v), phosphate buffer at a concentration of about 50 mM, and/or arginine at a concentration of about 0.5 M, and has a pH of about 9.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M, benzyl alcohol at a concentration of about 2% (v/v), phosphate buffer at a concentration of about 50 mM, and arginine at a concentration of about 0.5 M, and has a pH of about 9.0.
- a wash solution of the present disclosure comprises sodium benzoate, benzyl alcohol, and/or arginine, and has a pH of about 6.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M, benzyl alcohol at a concentration of about 2% (v/v), and/or arginine at a concentration of about 0.5 M, and has a pH of about 6.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M, benzyl alcohol at a concentration of about 2% (v/v), and arginine at a concentration of about 0.5 M, and has a pH of about 6.0.
- a wash solution of the present disclosure comprises hexylene glycol, sodium benzoate, and/or benzyl alcohol, and has a pH of about 7.0.
- the wash solution comprises hexylene glycol at a concentration of about 10% (v/v), sodium benzoate at a concentration of about 0.5 M, and/or benzyl alcohol at a concentration of about 2% (v/v), and has a pH of about 7.0.
- the wash solution comprises hexylene glycol at a concentration of about 10% (v/v), sodium benzoate at a concentration of about 0.5 M, and benzyl alcohol at a concentration of about 2% (v/v), and has a pH of about 7.0.
- a wash solution of the present disclosure comprises benzenesulfonate, sodium benzoate, and/or benzyl alcohol, and has a pH of about 7.0.
- the wash solution comprises benzenesulfonate at a concentration of about 0.5 M, sodium benzoate at a concentration of about 0.5 M, and/or benzyl alcohol at a concentration of about 2% (v/v), and has a pH of about 7.0.
- the wash solution comprises benzenesulfonate at a concentration of about 0.5 M, sodium benzoate at a concentration of about 0.5 M, and benzyl alcohol at a concentration of about 2% (v/v), and has a pH of about 7.0.
- a wash solution of the present disclosure comprises sodium benzoate, benzyl alcohol, and/or arginine (e.g ., arginine-HCl), and has a pH of about 5.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M, benzyl alcohol at a concentration of about 2% (v/v), and/or arginine (e.g., arginine-HCl) at a concentration of about 0.5 M, has a pH of about 5.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M, benzyl alcohol at a concentration of about 2% (v/v), and arginine (e.g, arginine-HCl) at a concentration of about 0.5 M, has a pH of about 5.0.
- arginine e.g, arginine-HCl
- a wash solution of the present disclosure comprises sodium benzoate, benzyl alcohol, and/or arginine (e.g, arginine-HCl), and has a pH of about 6.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M, benzyl alcohol at a concentration of about 2% (v/v), and/or arginine (e.g, arginine-HCl) at a concentration of about 0.5 M, has a pH of about 6.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M, benzyl alcohol at a concentration of about 2% (v/v), and arginine (e.g, arginine-HCl) at a concentration of about 0.5 M, has a pH of about 6.0.
- arginine e.g, arginine-HCl
- a wash solution of the present disclosure comprises benzyl alcohol and/or arginine (e.g, arginine-HCl), and has a pH of about 5.0.
- the wash solution comprises benzyl alcohol at a concentration of about 2% (v/v) and/or arginine (e.g, arginine-HCl) at a concentration of about 0.5 M, and has a pH of about 5.0.
- the wash solution comprises benzyl alcohol at a
- concentration of about 2% (v/v) and arginine e.g, arginine-HCl
- concentration of about 2% (v/v) and arginine e.g, arginine-HCl
- arginine e.g, arginine-HCl
- a wash solution of the present disclosure comprises sodium benzoate, arginine (e.g, arginine-HCl), caprylic acid, and/or sodium chloride, and has a pH of about 9.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M, arginine (e.g, arginine-HCl) at a concentration of about 0.5 M, caprylic acid at a concentration of about 50 mM, and/or sodium chloride at a concentration of about 0.5M, having a pH of about 9.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M, arginine (e.g ., arginine-HCl) at a concentration of about 0.5 M, caprylic acid at a concentration of about 50 mM, and sodium chloride at a concentration of about 0.5M, having a pH of about 9.0.
- arginine e.g ., arginine-HCl
- caprylic acid at a concentration of about 50 mM
- sodium chloride at a concentration of about 0.5M, having a pH of about 9.0.
- a wash solution of the present disclosure comprises sodium benzoate, arginine (e.g., arginine-HCl), caprylic acid, and/or sodium chloride, and has a pH of about 7.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M, arginine (e.g, arginine-HCl) at a concentration of about 0.5 M, caprylic acid at a concentration of about 50 mM, and/or sodium chloride at a concentration of about 0.5M, having a pH of about 7.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M, arginine (e.g, arginine-HCl) at a concentration of about 0.5 M, caprylic acid at a concentration of about 50 mM, and sodium chloride at a concentration of about 0.5M, having a pH of about 7.0.
- arginine e.g, arginine-HCl
- caprylic acid at a concentration of about 50 mM
- sodium chloride at a concentration of about 0.5M, having a pH of about 7.0.
- a wash solution of the present disclosure comprises sodium benzoate and/or sodium bicarbonate, and has a pH of about 10.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M and/or sodium bicarbonate at a concentration of about 50 mM, and has a pH of about 10.0.
- the wash solution comprises sodium benzoate at a concentration of about 0.5 M and sodium bicarbonate at a concentration of about 50 mM, and has a pH of about 10.0.
- a wash solution of the present disclosure comprises benzyl alcohol at a concentration of about 4% (v/v), and has a pH of about 5.0 to about 10. In some embodiments, the wash solution comprises benzyl alcohol at a concentration of about 4% (v/v), and has a pH of about 9.0.
- a method of purifying a polypeptide comprising an Fc region comprising the steps of: (A) adjusting (A) adjusting a harvest comprising the polypeptide comprising the Fc region to achieve a final concentration of a benzoate salt of about 0.1M and about 0.5M and a pH between about 7.0 and about 9.0 to produce a sample comprising (i) the polypeptide comprising the Fc region, and (ii) one or more impurities; and (B) contacting the sample with at least one chromatography matrix.
- the at least one chromatography matrix is an affinity chromatography matrix, e.g., a Protein A chromatography matrix and/or a protein G chromatography matrix.
- the method further comprising a step of contacting the at least one chromatography matrix with at least one wash solution. In some embodiments, the method further comprises a step of contacting the at least one chromatography matrix with an elution solution. In some embodiments, the method further comprises the step of collecting an eluate comprising the polypeptide comprising the Fc region.
- the term“harvest” refers to the fluid present at the end of cell culture or after cell culture, e.g., a cell lysate sample, or a cell culture supernatant sample (e.g, a supernatant from cells, such as CHO cells, engineered to produce and secrete the polypeptide).
- the harvest comprises intact host cells and/or cellular debris. In some embodiments, the harvest does not comprise intact host cells and/or cellular debris.
- the fluid present at the end of cell culture or after cell culture is subject to one or more centrifugation and/or filtration steps prior to adjustment to achieve a final concentration of a benzoate salt of about 0.1M and about 0.5M and a pH between about 7.0 and about 9.0.
- the harvest is derived from the fluid present at the end of cell culture or after cell culture.
- the fluid present at the end of cell culture or after cell culture is subject to one or more pre- treatment steps to optimize for cell separation and/or purification of the polypeptide comprising an Fc region.
- any one of the methods of purifying a polypeptide comprising an Fc region described herein further comprises a step of adjusting a harvest that comprises a polypeptide comprising an Fc region to achieve a final concentration of a benzoate salt of 0.1 M and about 0.5 M and a pH between about 7.0 and about 9.0 to produce the sample comprising (i) the polypeptide comprising the Fc region, and (ii) one or more impurities.
- the benzoate salt is a benzoate alkali salt.
- the benzoate salt is sodium benzoate.
- the harvest is adjusted to achieve a final concentration of a benzoate salt (e.g., sodium benzoate) of about any one of 0.025 M, 0.05 M, 0.075 M, 0.1 M, 0.125 M, 0.15 M, 0.175 M, 0.2 M, 0.225 M, 0.25 M, 0.275 M, 0.3 M, 0.325 M, 0.35 M, 0.375 M, 0.4 M 0.425 M, 0.45 M, 0.475 M, 0.5 M, 0.525 M, 0.55 M 0.575 M, 0.6 M, 0.625 M, 0.65 M, 0.675 M, 0.7 M, 0.725 M, 0.75 M.
- a benzoate salt e.g., sodium benzoate
- the pH of the harvest is adjusted to about any one of 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, or 10.0, including any range in between these values.
- the harvest is clarified prior to adjustment (e.g., addition of sodium benzoate and adjustment of pH). In some embodiments, the harvest is clarified following adjustment (e.g., addition of sodium benzoate and adjustment of pH).
- the method comprises adjusting the harvest to achieve a final sodium benzoate concentration of about 0.5 M and a pH of about 7. In some embodiments, the method comprises adjusting the harvest to achieve a final sodium benzoate concentration of about 0.1 M and a pH of about 9. In some embodiments, the method comprises adjusting the harvest to achieve a final sodium benzoate concentration of about 0.2 M and a pH of 9.
- the method comprises adjusting the harvest to achieve a final sodium benzoate concentration of about 0.3 M and a pH of 9. In some embodiments, the method comprises adjusting the harvest to achieve a final sodium benzoate concentration of about 0.4 M and a pH of 9. In some embodiments, the method comprises adjusting the harvest to achieve a final sodium benzoate concentration of about 0.5 M and a pH of 9.
- adjusting the harvest results in the polypeptide comprising the Fc region being purified away from the one or more impurities to a higher degree than a corresponding method lacking the step of adjusting the harvest comprising the polypeptide comprising the Fc region to produce the sample.
- one or more impurities are host cell proteins (HCPs), such as phospholipases, clusterin, serine proteases, elongation factors, and any combinations thereof.
- HCP is Putative Phospholipase B4ike 2 (PLBL2).
- the adjusted harvest (e.g., to which sodium benzoate has been added to achieve a final concentration described herein and the pH of which has been adjusted as described herein) comprises or is the sample comprising (i) the polypeptide comprising the Fc region, and (ii) one or more impurities.
- the sample is contact with at least one chromatography matrix (e.g., the sample is subject to at least one chromatography step).
- the at least one chromatography matrix comprises any one or more of: an affinity chromatography matrix, a mixed-mode
- the sample is contacted with an affinity chromatography matrix, e.g., a Protein A matrix or a Protein G matrix.
- the method further comprising a step of contacting the at least one chromatography matrix with at least one wash solution.
- the method further comprises a step of contacting the at least one chromatography matrix with an elution solution.
- the method further comprises the step of collecting an eluate comprising the polypeptide comprising the Fc region.
- Certain aspects of the present disclosure relate to methods of purifying a polypeptide comprising an Fc region via protein A chromatography by washing a protein A matrix bound to the polypeptide comprising an Fc region (e.g., an antibody) with a wash solution comprising a benzoate salt and/or benzyl alcohol, in order to improve purification of the polypeptide away from one or more impurities.
- a protein A matrix bound to the polypeptide comprising an Fc region e.g., an antibody
- a wash solution comprising a benzoate salt and/or benzyl alcohol
- the method comprises the steps of: contacting a protein A chromatography matrix with a sample comprising (1) a polypeptide comprising an Fc region (e.g, an antibody) and (2) one or more impurities (e.g, host cell impurities) under a condition that the polypeptide comprising the Fc region (e.g, the antibody) binds to protein A; and washing the matrix with a wash solution comprising a benzoate salt at a concentration of about 0.1 M to about 1.0 M and/or benzyl alcohol at a concentration of about 0.5% to about 4% volume/volume (v/v), where the wash solution has a pH of about 4.0 to about 10.0.
- a wash solution comprising a benzoate salt at a concentration of about 0.1 M to about 1.0 M and/or benzyl alcohol at a concentration of about 0.5% to about 4% volume/volume (v/v)
- washing the protein A matrix with the wash solution results in the polypeptide comprising the Fc region being purified away from the one or more impurities to a higher degree than a corresponding method (as described above) lacking the step of washing the matrix with the wash solution.
- a standard protein A process typically results in a product purity of about 95% without the use of a wash step as described herein.
- the largest proportions of the impurities in the product are due to high molecular weight (HMW) aggregates and/or low molecular weight (LMW) fragments of the product.
- HMW high molecular weight
- LMW low molecular weight
- These product variants are considered impurities due to their ability to be separated from the product based on various parameters (e.g, charge, hydrophobicity, size difference, etc.).
- HMW and LMW impurities account for about 4-5% of the protein A pool.
- a standard protein A process lacking the use of a wash step as described herein also typically results in the inclusion of host cell protein (HCP) impurities on the order of 1000 ppm or ⁇ 0.1% of the product pool.
- HCP host cell protein
- the inclusion of a step applying a wash solution described herein may reduce the amount of HCPs present in the pool to -100-10 ppm (a 10 to lOO-fold reduction in HCPs relative to the same protein A process lacking the wash step described herein), accounting for a 90-99 % relative improvement.
- sample protein purity and/or impurity levels are generally known to one of ordinary skill in the art.
- An exemplary purification of a monoclonal antibody (mAb) away from one or more host cell proteins using a standard method vs. any of the methods described herein is shown in Table A below.
- the methods described herein produce a protein pool containing a polypeptide comprising an Fc region (e.g ., a monoclonal antibody) after protein A elution that contains less than about 500 ppm (parts per million) of HCPs (e.g., one or more HCPs from a CHO cell).
- a polypeptide comprising an Fc region e.g ., a monoclonal antibody
- HCPs e.g., one or more HCPs from a CHO cell.
- a protein pool containing a polypeptide comprising an Fc region produced by the methods described herein may contain less than about 500 ppm, less than about 450 ppm, less than about 400 ppm, less than about 350 ppm, less than about 300 ppm, less than about 250 ppm, less than about 200 ppm, less than about 150 ppm, less than about 100 ppm, less than about 75 ppm, less than about 50 ppm, less than about 25 ppm, less than about 10 ppm, or less than about 1 ppm of HCPs ( e.g ., one or more HCPs from a CHO cell).
- HCPs e.g ., one or more HCPs from a CHO cell
- a protein pool containing a polypeptide comprising an Fc region produced by the methods described herein contains less than about 100 ppm of HCPs (e.g., one or more HCPs from a CHO cell). In some embodiments, a protein pool containing a polypeptide comprising an Fc region produced by the methods described herein contains less than about 10 ppm of HCPs (e.g, one or more HCPs from a CHO cell).
- the methods described herein produce a protein pool containing a polypeptide comprising an Fc region (e.g, a monoclonal antibody) after protein A elution that contains less than about 0.1% HCPs (e.g, one or more HCPs from a CHO cell).
- Fc region e.g, a monoclonal antibody
- HCPs e.g, one or more HCPs from a CHO cell
- a protein pool containing a polypeptide comprising an Fc region produced by the methods described herein may contain less than about less than about 0.1%, less than about 0.09%, less than about 0.08%, less than about 0.07%, less than about 0.06%, less than about 0.05%, less than about 0.04%, less than about 0.03%, less than about 0.02%, or less than about 0.01% HCPs (e.g, one or more HCPs from a CHO cell).
- a protein pool containing a polypeptide comprising an Fc region produced by the methods described herein contains less than about 0.05% HCPs (e.g, one or more HCPs from a CHO cell).
- a protein pool containing a polypeptide comprising an Fc region produced by the methods described herein contains less than about 0.01% HCPs (e.g, one or more HCPs from a CHO cell).
- the methods described herein reduce the amount and/or concentration (e.g, parts per million) of one or more impurities (e.g, one or more HCPs such as one or more HCPs from a CHO cell) co-purified with the polypeptide comprising the Fc region by at least about 10% relative to the amount of the one or more impurities co-purified with a polypeptide comprising an Fc region purified by a corresponding method lacking the step of washing the protein A matrix with the wash solution.
- one or more impurities e.g, one or more HCPs such as one or more HCPs from a CHO cell
- the methods described herein reduce the amount and/or concentration (e.g, parts per million) of one or more impurities (e.g, one or more HCPs such as one or more HCPs from a CHO cell) co- purified with the polypeptide comprising the Fc region by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% or at least about 99% relative to the amount of one or more impurities co-purified with a polypeptide comprising an Fc region purified by a corresponding method lacking the step of washing the protein A matrix with the wash solution.
- impurities e.g, one or more HCPs such as one or more HCPs from a CHO cell
- the methods described herein reduce the amount and/or concentration (e.g ., parts per million) of one or more impurities (e.g, one or more HCPs such as one or more HCPs from a CHO cell) co-purified with the polypeptide comprising the Fc region by at least about 1.5-fold relative to the amount of one or more impurities co-purified with a polypeptide comprising an Fc region purified by a corresponding method lacking the step of washing the protein A matrix with the wash solution.
- one or more impurities e.g, one or more HCPs such as one or more HCPs from a CHO cell
- the methods described herein reduce the amount and/or concentration (e.g, parts per million) of one or more impurities (e.g, one or more HCPs such as one or more HCPs from a CHO cell) co- purified with the polypeptide comprising the Fc region by at least about 1.5-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 4.5-fold, at least about 5-fold, at least about 5.5-fold, at least about 6- fold, at least about 6.5-fold, at least about 7-fold, at least about 7.5-fold, at least about 8-fold, at least about 8.5-fold, at least about 9-fold, at least about 9.5-fold, at least about lO-fold, at least about 50-fold, or at least about lOO-fold relative to the amount of one or more impurities co-purified with a polypeptide comprising an Fc region purified by a corresponding method lacking
- the methods described herein further comprise one or more additional wash steps. In some embodiments, the methods described herein further comprise one or more elution steps. In some embodiments, the methods described herein further comprise one or more wash steps and one or more elution steps.
- the present disclosure relates to washing the protein A matrix with a first solution prior to washing the matrix with the wash solution.
- the matrix is washed with the first solution one or more (e.g, one or more, two or more, three or more, four or more, five or more, etc.) times prior to washing the matrix with the wash solution.
- the matrix is washed once with the first solution prior to washing the matrix with the wash solution.
- the first solution comprises a buffer.
- any suitable buffer known in the art may be used in the first solution, including, for example, phosphate, tris (tris(hydroxymethyl)methylamine), acetate, carbonate, citrate, bis-tris, bis-tris propane, arginine, histidine, triethanolamine,
- the first solution comprises phosphate buffer, tris buffer, acetate buffer, carbonate buffer, and/or
- the first solution comprises phosphate buffer.
- the first solution comprises one or more additional components (e.g ., benzoate salt, benzyl alcohol, one or more additives described herein, etc.).
- the first solution has a pH of about 5.0 to about 10.0 (e.g., about 6.0 to about 10.0, about 6.0 to about 9.0, about 7.0 to about 10.0, about 7.0 to about 9.0, about 8.0 to about 10.0, about 8.0 to about 9.0, about 9.0 to about 10.0, about 5.0 to about 8.0, about 6.0 to about 8.0, about 7.0 to about 8.0, about 5.0 to about 7.0, about 6.0 to about 7.0, or about 5.0 to about 6.0).
- the first solution has a pH of about 7.0.
- the first solution comprises the buffer at a concentration of about 10 mM to about 100 mM or about 10 mM to about 500 mM.
- the first solution may comprise the buffer at a concentration of about 10 mM to about 500 mM, about 100 mM to about 500 mM, about 150 mM to about 500 mM, about 200 mM to about 500 mM, about 250 mM to about 500 mM, about 300 mM to about 500 mM, about 350 mM to about 500 mM, about 400 mM to about 500 mM, about 450 mM to about 500 mM, about 10 mM to about 450 mM, about 10 mM to about 400 mM, about 10 mM to about 350 mM, about 10 mM to about 300 mM, about 10 mM to about 250 mM, about 10 mM to about 200 mM, about 10 mM to about 150 mM, about 10
- the first solution comprises the buffer at a concentration of any of about 10 mM, 15 mM, 20 mM, 25mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM,
- the first solution comprises the buffer at a concentration of any of about 150 mM, 200 mM, 250 mM, 300 mM, 350 mM, 400 mM, 450 mM, or 500 mM. In some embodiments, the first solution comprises the buffer at a concentration of about 500 mM. In some embodiments, the first solution comprises the buffer at a concentration of about 50 mM. In some embodiments, the first solution comprises phosphate buffer at a concentration of about 500 mM. In some embodiments, the first solution comprises phosphate buffer at a concentration of about 50 mM.
- the first solution comprises phosphate buffer ( e.g ., sodium phosphate) and sodium chloride.
- the first solution comprises phosphate buffer (e.g., sodium phosphate) and sodium chloride, and has a pH of about 7.0.
- the first solution comprises phosphate buffer (e.g, sodium phosphate) at a concentration of about 50 mM, and sodium chloride at a concentration of about 0.5 M.
- the first solution comprises phosphate buffer (e.g, sodium phosphate) at a concentration of about 50 mM, and sodium chloride at a concentration of about 0.5 M, and had a pH of about 7.0.
- the present disclosure relates to washing the protein A matrix with a second solution after washing the matrix with the wash solution.
- the matrix is washed with the second solution one or more (e.g, one or more, two or more, three or more, four or more, five or more, etc.) times after washing the matrix with the wash solution.
- the matrix is washed once with the second solution after washing the matrix with the wash solution.
- the second solution comprises a buffer.
- any suitable buffer known in the art may be used in the second solution, including, for example, phosphate, tris (tris(hydroxymethyl)methylamine), acetate, carbonate, citrate, bis-tris, bis-tris propane, arginine, histidine, triethanolamine,
- the second solution comprises phosphate buffer, tris buffer, acetate buffer, carbonate buffer, and/or
- the second solution comprises phosphate buffer. In some embodiments, the second solution comprises substantially low salt or no salt. In some embodiments, the second solution has a pH of about 4.0 to about 8.0 ( e.g about 5.0 to about 8.0, about 6.0 to about 8.0, about 7.0 to about 8.0, about 4.0 to about 7.0, about 5.0 to about 7.0, about 6.0 to about 7.0, about 4.0 to about 6.0, about 5.0 to about 6.0, or about 4.0 to about 5.0). In some embodiments, the second solution has a pH of about 5.0 to about 7.0. In some embodiments, the second solution has a pH of about 7.0. In some embodiments, the second solution comprises substantially low salt. In some embodiments, the second solution comprises no salt.
- the second solution comprises the buffer at a concentration of about 10 mM to about 100 mM or about 10 mM to about 500 mM.
- the second solution may comprise the buff at a concentration of about 10 mM to about 500 mM, about 100 mM to about 500 mM, about 150 mM to about 500 mM, about 200 mM to about 500 mM, about 250 mM to about 500 mM, about 300 mM to about 500 mM, about 350 mM to about 500 mM, about 400 mM to about 500 mM, about 450 mM to about 500 mM, about 10 mM to about 450 mM, about 10 mM to about 400 mM, about 10 mM to about 350 mM, about 10 mM to about 300 mM, about 10 mM to about 250 mM, about 10 mM to about 200 mM, about 10 mM to about 150 mM, about 10
- the second solution comprises the buffer at a
- the second solution comprises the buffer at a concentration of any of about 150 mM, 200 mM, 250 mM, 300 mM, 350 mM, 400 mM, 450 mM, or 500 mM. In some embodiments, the second solution comprises the buffer at a concentration of about 500 mM. In some embodiments, the second solution comprises the buffer at a concentration of about 50 mM.
- the second solution comprises phosphate buffer (e.g ., sodium phosphate).
- the second solution comprises phosphate buffer (e.g., sodium phosphate), and has a pH of about 7.0.
- the second solution comprises phosphate buffer (e.g, sodium phosphate) at a concentration of about 50 mM.
- the second solution comprises phosphate buffer (e.g, sodium phosphate) at a concentration of about 50 mM, and had a pH of about 7.0.
- the methods of the present disclosure relate to washing a protein A matrix with a wash solution, and do not include a step of washing the matrix with a first solution (prior to the wash solution) or a second solution (after the wash solution). In some embodiments, the methods of the present disclosure relate to washing a protein A matrix with a first solution, then washing the matrix with a wash solution, and do not include a step of washing the matrix with a second solution (after the wash solution). In some embodiments, the methods of the present disclosure relate to washing a protein A matrix with a wash solution and then washing the matrix with a second solution, and do not include a step of washing the matrix with a first solution (prior to the wash solution). In some embodiments, the methods of the present disclosure relate to washing a protein A matrix with a first solution, then washing the matrix with a wash solution, and then washing the matrix with a second solution.
- the protein A matrix is contacted with an elution solution one or more (e.g, one or more, two or more, three or more, four or more, five or more, etc.) times after one or more washing steps.
- the matrix is contacted with the elution solution one time.
- Any solution known in the art suitable for eluting a polypeptide bound to a protein A matrix may be used as an elution solution in the methods of the present disclosure (e.g ., an elution solution comprising 40 mM sodium acetate having a pH of about 3.1).
- the elution solution further comprises one or more additional components (e.g., arginine at any of the concentrations described herein).
- an eluate comprising the polypeptide comprising the Fc region is collected after contacting the matrix with the elution solution.
- two or more eluates comprising the polypeptide comprising the Fc region are collected after contacting the matrix two or more times with the elution solution.
- the two or more eluates are combined after elution.
- the eluate(s) are filtered. Any suitable method of filtering an eluate known in the art may be used including, for example, via depth filtration. In some embodiments, the eluate(s) are filtered via depth filtration.
- eluates from a protein A matrix as described herein may be further processed and/or purified (e.g, using an additional chromatography and/or filtration step (such as by use of one or more of ion exchange chromatography, mixed-mode chromatography, affinity chromatography, hydrophobic interaction chromatography, immobilized metal affinity chromatography, size exclusion chromatography, diafiltration, ultrafiltration, and/or viral removal filtration)), and/or formulated (e.g, preparing a pharmaceutical formulation suitable for administration to a subject in need thereof (such as a human subject)).
- an additional chromatography and/or filtration step such as by use of one or more of ion exchange chromatography, mixed-mode chromatography, affinity chromatography, hydrophobic interaction chromatography, immobilized metal affinity chromatography, size exclusion chromatography, diafiltration, ultrafiltration, and/or viral removal filtration
- formulated e.g, preparing a pharmaceutical formulation suitable for administration to a subject in need thereof (such as
- Example 1 wash solutions for improving or enhancing removal of impurities during antibody purification
- Two separate human monoclonal antibody harvest materials were prepared for protein A chromatography as follows: harvest was generated in a suspension culture of recombinant Chinese Hamster Ovary (CHO) cells engineered to constitutively express either one of the antibodies. The recombinant product was secreted into the culture medium which was then centrifuged and clarified by depth filtration for downstream processing. Clarified harvest material was filtered with a 0.22 pm polyethersulfone (PES) filter prior to loading on the protein A column.
- PES polyethersulfone
- Protein A resin/columns were prepared as follows: MabSelect Sure LX protein A chromatography resin (GE Healthcare Life Sciences; cat. No. 17-5474) was exchanged via gravity settling with 0.5 M sodium chloride solution. Columns were packed using an AKTA Pure or AKTA Avant (GE Healthcare Life Sciences) using either (A) a 1.0 cm diameter column (Essential Life Solutions 10/250 Snap Column; cat. no. S10/250-PPSL-OE-FP10) or (B) a 0.66 cm diameter column (OmnifitTM 6.6/100; cat. no. 006BCC0610FF).
- the resin was packed to a bed height of 20 cm ⁇ 10% for column (A), or to a bead height of 5 cm ⁇ 10% for column (B).
- Column qualification was performed using a 1% column volume injection of 1.0 M sodium chloride solution onto the column equilibrated in 0.1 M sodium chloride solution, and the conductivity trace was analyzed using ETnicorn Evaluation software. The efficiency of the column needed to be at least 775 theoretical plates per meter, and needed to demonstrate an asymmetry of 0.8-1.8.
- columns Prior to loading the harvest material, columns were flushed with reverse osmosis deionization water to remove storage buffer of 20% ethanol.
- the column was flushed with 0.5 M acetic acid to ensure removal of any bound entities prior to equilibration.
- the column was equilibrated with 50 mM phosphate buffer with 0.5 M sodium chloride until the pH of the column was >6.5.
- HCP host cell protein
- the HCP ELISA was performed at dilutions between 1 :400 and 1 :800, and absorbance was read at 450/600 nm using a Spectramax Plus 384 plate reader.
- HCP-A concentration of a specific HCP
- CHO Hamster
- ICL Labs a commercially available Hamster ELISA kit
- the HCP-A ELISA was performed at dilutions between 1 :100 and 1 :800, and absorbance was read at 450 nm using a Spectramax Plus 384 plate reader.
- HCPs Host cell proteins
- mAbs monoclonal antibodies
- a 1.7 mL protein A chromatography column was loaded with a sample containing a secreted IgGl human monoclonal antibody (mAh A) harvested from CHO cells that had been both centrifuged and clarified by depth filtration prior to downstream processing ( See Table 1). The columns were first washed with a phosphate buffer solution.
- the columns were washed with one of a number of test wash solutions containing 50 mM phosphate and an additive, either individually or as a combination with sodium benzoate, benzyl alcohol, and arginine, at pH 7.0 (FIG. 1). Control runs did not incorporate any additive wash.
- the columns were washed with salt free 50 mM phosphate, pH 7.0.
- the monoclonal antibody was eluted from the column and pH adjusted to a pH of 6.0 using 2 M tris base. After adjustment, the eluate pools were filtered using a 0.22 pm PES filter, and were tested for the presence of HCP impurities (FIG. 1).
- washes containing 2% benzyl alcohol and/or 0.5 M sodium benzoate effectively reduced the levels of contaminating HCPs in the eluted antibody samples.
- the inclusion of arginine in the wash was also observed to improve HCP clearance.
- test solution 8 or 9 (Table 2) was when applied for two CVs, and immediately followed by three CVs of salt-free phosphate buffer solution at pH 7.0. After elution with 40 mM sodium acetate, the eluate pools were adjusted to pH 5.5 using 2 M tris base. Eluate pools were then filtered with a 0.22 pm PES filter. As shown in FIG. 2B, 0.5 M sodium benzoate with a buffering salt at pH 10.0 was highly effective at removing HCP-A (92% reduction) relative to the control.
- Example 2 Identification of specific host cell proteins present following protein A chromatography, development of wash solutions for improving or enhancing removal of impurities during antibody purification, and assessment of Putative Phospholipase B- like 2 interaction with human monoclonal antibody
- HCPs Hypophospholipase B-like 2
- PLBL2 Putative Phospholipase B-like 2
- Human monoclonal antibody harvest materials were prepared for protein A chromatography as described in Example 1. Briefly, harvest was generated in a suspension culture of recombinant CHO cells engineered to constitutively express either one of the human monoclonal antibodies. The recombinant product was secreted into the culture medium which was then centrifuged and clarified by depth filtration for downstream processing. Clarified harvest material was filtered with a 0.22 pm polyethersulfone (PES) filter prior to loading on the protein A column.
- PES polyethersulfone
- Protein A resin/columns were prepared as described in Example 1. Briefly,
- Mab Select Sure LX Protein A chromatography resin (GE Healthcare Life Sciences; cat. No. 17-5474) was exchanged via gravity settling with 0.5 M sodium chloride solution. Columns were packed using an AKTA Pure or AKTA Avant (GE Healthcare Life Sciences) using either (A) a 1.0 cm diameter column (Essential Life Solutions 10/250 Snap Column; cat. no. S10/250-PPSL-OE-FP10) or (B) a 0.66 cm diameter column (OmnifitTM 6.6/100; cat. no. 006BCC0610FF). The resin was packed to a bed height of 20 cm ⁇ 10% for column (A), or to a bead height of 5 cm ⁇ 10% for column (B).
- Samples were first denatured using 0.05% Rapigest in 50mM Ammonium Bicarbonate and then reduced and alkylated using 20 mM DTT (dithiothreitol) and 40 mM IAA (Iodoacetamide). Enzymatic digestion was performed by 2% LysC overnight followed by 3 hours with 4% Trypsin.
- Rapigest was removed via centrifugation and samples were acidified using formic acid.
- a spike-in internal standard of 2.5 fmol/ul of ClpB E.coli was then added to compare relative amounts of HCP and PLBL2.
- a lock mass calibration was performed around 785.8426 m/z.
- MS E was used to analyze the ion data and identify HCPs. HCP detection by ELISA
- HCP ELISA Kit 3 rd Generation CHO HCP ELISA Kit (Cygnus Technologies) according to the manufacturer’s protocol.
- the HCP ELISA was performed at dilutions between 1 :400 and 1 :800, and absorbance was read at 450/600 nm using a Spectramax Plus 384 plate reader.
- the concentration of a PLBL2 was quantified in the eluted antibody samples using a commercially available Hamster (CHO) ELISA kit (ICL Labs , E-65PLB) in accordance with the manufacturer’s protocol.
- the PLBL2 ELISA was performed at dilutions between 1 :100 and 1 :800, and absorbance was read at 450 nm using a Spectramax Plus 384 plate reader.
- HCPs have been shown to co-elute with human monoclonal antibody, which may be problematic for downstream applications of these antibodies.
- a 1.7 mL protein A chromatography column was loaded with a sample containing a secreted IgGl human monoclonal antibody (mAh A) harvested from CHO cells that had been both centrifuged and clarified by depth filtration prior to downstream processing ( See Table 1). The columns were first washed with a phosphate buffer solution. Next, the columns were washed with salt free 50 mM phosphate, pH 7.0.
- the monoclonal antibody was eluted from the column and pH adjusted to a pH of 6.0 using 2 M tris base. After adjustment, the eluate pools were filtered using a 0.22 pm PES filter, and were analyzed by Mass Spectrometry to identify relative amounts of HCPs. Notably, Clusterin and PLBL2 were the two most abundant HCPs present in the human monoclonal antibody eluate. Identification of Intermediate Wash Conditions to Improve HCP/PLBL2 Removal.
- HCPs including PLBL2
- HCPs co-elute with human monoclonal antibodies following protein A purification.
- ELISA screens were developed to identify intermediate wash solutions that could be used to further improve and enhance HCP and PLBL2 removal (FIG. 4A and 4B).
- intermediate washes comprising 4% benzyl alcohol or 0.5 M sodium benzoate effectively reduced the levels of contaminating HCPs and PLBL2 in the antibody eluate samples. Washes containing 0.5 M Arginine alone did not reduce level of generic HCPs, but did reduce the level of contaminating PLBL2.
- PLBL2 ELISA screens further show that deep filtering combined with intermediate washes comprising: 1) 2% benzyl alcohol and 0.5 M arginine pH 5.0, 2) 2% benzyl alcohol and 0.5 M sodium benzoate pH 7.0, or 3) 2% benzyl alcohol, 0.5 M sodium benzoate, 0.5 M arginine pH 6.0, effectively removed PLBL2 during protein A purification.
- washes with elevated pH levels (0.5 M sodium benzoate and 50 mM sodium bicarbonate pH 10.0 or 2% benzyl alcohol, 0.5 M sodium benzoate, 0.5 M arginine, and 50 mM sodium phosphate pH 9.0) were highly effective at removing PLBL2 during protein A purification.
- sodium benzoate wash with 50 mM sodium bicarbonate pH 10.0 was able to remove more than 92% of PLBL2 compared to control treatment.
- washes comprising: 1) 0.5 M sodium benzoate, 2% benzyl alcohol, and 0.5 M benzenesulfonate pH 7.0, 2) 0.5 M sodium benzoate, 50 mM caprylic acid, 0.5 M arginine, and 0.5 M sodium chloride pH 7.0, 3) 0.5 M sodium benzoate, 2% benzyl alcohol, and 10% hexylene glycol pH 7.0, or 4) 0.5 M sodium benzoate, 2% benzyl alcohol, and 0.5 M arginine pH 6.0, demonstrated robust ability to remove PLBL2 compared to control washes.
- PLBL2 ELISAs demonstrate that intermediate wash containing benzyl alcohol and sodium benzoate can effectively reduce the level of PLBL2 in protein A purified antibody eluate.
- This result was further confirmed orthogonally through Mass Spectrometry.
- the Mass Spectrometry results show that test wash 0.5 M Sodium Benzoate, 0.5 M Arginine, 50 mM Caprylic Acid, 0.5 M NaCl pH 9.0 removed nearly 93% of PLBL2 from the eluate relative to the control treatment.
- the data provided in this example show that PLBL2 is among the host cell proteins that co-elute with human monoclonal antibody following protein A purification. Further, the data demonstrate that an intermediate wash step containing sodium benzoate and/or benzyl alcohol was able to provide superior clearance of host cell protein impurities and PLBL2 during protein A purification of a human monoclonal antibody. Moreover, the data show that overloading the protein A resin column can decrease off- column yield and PLBL2 removal.
- Example 3 Assessing the effects of pH and benzoate salt concentration in a harvest comprising an antibody on the removal of impurities during antibody purification.
- Human monoclonal antibody harvests were prepared as described in Example 1. The clarified and depth filtered harvest was adjusted to varying pH and additive concentrations to screen for impacts on HCP and PLBL2 clearance.
- Sodium benzoate previously shown to be effective for PLBL2 removal as part of an additional wash step, was added as a solid in quantities sufficient to reach a target final concentration for a given volume of harvest. After addition, the target pH was reached through addition of 2 M tris base.
- a first harvest was supplemented with sodium benzoate to achieve a final concentration of 0.5 M sodium benzoate and adjusted to a pH of 7.2.
- a second harvest was supplemented with sodium benzoate to achieve a final concentration of 0.5 M sodium benzoate and adjusted to a pH of 9.
- a third harvest was adjusted to a pH of 9 (no sodium benzoate was added). See
- HCP host cell protein
- FIG. 8 shows the relationship between PLBL2 content and sodium benzoate concentration is approximately sigmoidal. Diminished gains in clearance of PLBL2 were observed for concentrations above 0.4 M sodium benzoate. Antibody yield decreased slightly with increasing concentration of sodium benzoate. From 0.1 M to 0.5 M sodium benzoate, antibody yield decreased from 94.8% to 89.4%. Highest yield and highest PLBL2 clearance were observed when the harvest was adjusted to 0.4 M sodium benzoate and pH 9.0 prior to Protein A purification.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Water Supply & Treatment (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21217361.1A EP4050016A1 (en) | 2017-12-21 | 2018-12-20 | Methods for enhanced removal of impurities during protein a chromatography |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762609214P | 2017-12-21 | 2017-12-21 | |
US201862694387P | 2018-07-05 | 2018-07-05 | |
PCT/US2018/066890 WO2019126554A1 (en) | 2017-12-21 | 2018-12-20 | Methods for enhanced removal of impurities during protein a chromatography |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21217361.1A Division EP4050016A1 (en) | 2017-12-21 | 2018-12-20 | Methods for enhanced removal of impurities during protein a chromatography |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3728288A1 true EP3728288A1 (en) | 2020-10-28 |
EP3728288B1 EP3728288B1 (en) | 2022-01-19 |
Family
ID=65241305
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21217361.1A Pending EP4050016A1 (en) | 2017-12-21 | 2018-12-20 | Methods for enhanced removal of impurities during protein a chromatography |
EP18842505.2A Active EP3728288B1 (en) | 2017-12-21 | 2018-12-20 | Methods for enhanced removal of impurities during protein a chromatography |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21217361.1A Pending EP4050016A1 (en) | 2017-12-21 | 2018-12-20 | Methods for enhanced removal of impurities during protein a chromatography |
Country Status (18)
Country | Link |
---|---|
US (2) | US11236126B2 (en) |
EP (2) | EP4050016A1 (en) |
JP (2) | JP2021506925A (en) |
KR (1) | KR20200103740A (en) |
CN (1) | CN111712510B (en) |
AU (1) | AU2018392697A1 (en) |
BR (1) | BR112020012165A2 (en) |
CA (1) | CA3086186A1 (en) |
CY (1) | CY1125448T1 (en) |
DK (1) | DK3728288T3 (en) |
ES (1) | ES2907744T3 (en) |
HU (1) | HUE057850T2 (en) |
IL (2) | IL275418B2 (en) |
MX (1) | MX2020006586A (en) |
SG (1) | SG11202005809TA (en) |
TW (2) | TW202400623A (en) |
WO (1) | WO2019126554A1 (en) |
ZA (1) | ZA202003440B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220314142A1 (en) * | 2019-07-01 | 2022-10-06 | Pfizer Inc. | Improvements to wash solutions for protein a chromatography in an antibody purification process |
CN112827217A (en) * | 2020-12-29 | 2021-05-25 | 苏州良辰生物医药科技有限公司 | Chromatographic column cleaning solution and application thereof |
WO2024017826A2 (en) * | 2022-07-19 | 2024-01-25 | Glaxosmithkline Intellectual Property Development Limited | Methods for purifying recombinant polypeptides |
CN115894604B (en) * | 2022-12-16 | 2024-01-23 | 康日百奥生物科技(苏州)有限公司 | Recombinant protein clarifying and purifying method |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4871667A (en) * | 1984-11-26 | 1989-10-03 | Agency Of Industrial Science & Technology | Process for preparing muconic acid |
US5750402A (en) * | 1995-06-02 | 1998-05-12 | Plant Cell Technology, Inc. | Compositions and methods to prevent microbial contamination of plant tissue culture media |
CA2604877A1 (en) * | 2005-04-11 | 2006-10-19 | J.P. Sercel Associates Inc. | Protein purification |
JP2006343214A (en) * | 2005-06-09 | 2006-12-21 | Matsushita Electric Ind Co Ltd | Immunoreaction measuring method, and reagent for immunoreaction measurement used therefor |
AU2007204987B2 (en) * | 2006-01-06 | 2011-11-24 | Amgen Inc. | Methods and systems for isolating target molecules from complex solutions by column-chromatography using eluants containing organic solvents |
EP2921501A1 (en) * | 2008-10-20 | 2015-09-23 | Abbvie Inc. | Isolation and purification of antibodies using Protein A affinity chromatography |
CN102712691A (en) * | 2009-08-06 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | Method to improve virus removal in protein purification |
ES2651065T3 (en) | 2009-12-18 | 2018-01-24 | Novartis Ag | Washing solution and method for affinity chromatography |
RU2610667C2 (en) * | 2010-10-11 | 2017-02-14 | Эббви Бахамаз Лтд., | Method of purification of proteins |
RU2661764C2 (en) * | 2011-05-27 | 2018-07-19 | Эббви Байотекнолоджи Лтд., | Compositions and methods based on dac hyp |
CN114560906A (en) * | 2013-09-04 | 2022-05-31 | Emd密理博公司 | Method for washing affinity chromatographic column based on protein A |
US20170066839A1 (en) * | 2015-09-08 | 2017-03-09 | Merck Patent Gmbh | Novel affinity chromatography media for removal of anti-a and/or anti-b antibodies |
-
2018
- 2018-12-20 SG SG11202005809TA patent/SG11202005809TA/en unknown
- 2018-12-20 HU HUE18842505A patent/HUE057850T2/en unknown
- 2018-12-20 IL IL275418A patent/IL275418B2/en unknown
- 2018-12-20 CN CN201880089518.3A patent/CN111712510B/en active Active
- 2018-12-20 MX MX2020006586A patent/MX2020006586A/en unknown
- 2018-12-20 WO PCT/US2018/066890 patent/WO2019126554A1/en unknown
- 2018-12-20 CA CA3086186A patent/CA3086186A1/en active Pending
- 2018-12-20 JP JP2020534539A patent/JP2021506925A/en active Pending
- 2018-12-20 KR KR1020207020808A patent/KR20200103740A/en not_active Application Discontinuation
- 2018-12-20 EP EP21217361.1A patent/EP4050016A1/en active Pending
- 2018-12-20 EP EP18842505.2A patent/EP3728288B1/en active Active
- 2018-12-20 BR BR112020012165-7A patent/BR112020012165A2/en unknown
- 2018-12-20 US US16/228,291 patent/US11236126B2/en active Active
- 2018-12-20 AU AU2018392697A patent/AU2018392697A1/en active Pending
- 2018-12-20 ES ES18842505T patent/ES2907744T3/en active Active
- 2018-12-20 IL IL311002A patent/IL311002A/en unknown
- 2018-12-20 DK DK18842505.2T patent/DK3728288T3/en active
- 2018-12-21 TW TW112133254A patent/TW202400623A/en unknown
- 2018-12-21 TW TW107146337A patent/TWI815838B/en active
-
2020
- 2020-06-09 ZA ZA2020/03440A patent/ZA202003440B/en unknown
-
2021
- 2021-12-17 US US17/554,758 patent/US20220242902A1/en active Pending
-
2022
- 2022-03-29 CY CY20221100241T patent/CY1125448T1/en unknown
-
2023
- 2023-08-04 JP JP2023127480A patent/JP2023145727A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018392697A1 (en) | 2020-08-06 |
IL275418A (en) | 2020-08-31 |
TW202400623A (en) | 2024-01-01 |
IL275418B1 (en) | 2024-03-01 |
TWI815838B (en) | 2023-09-21 |
RU2020123917A3 (en) | 2022-01-26 |
CN111712510B (en) | 2024-06-14 |
DK3728288T3 (en) | 2022-03-28 |
JP2021506925A (en) | 2021-02-22 |
CY1125448T1 (en) | 2024-02-16 |
RU2020123917A (en) | 2022-01-26 |
TW201936629A (en) | 2019-09-16 |
ZA202003440B (en) | 2021-10-27 |
IL311002A (en) | 2024-04-01 |
ES2907744T3 (en) | 2022-04-26 |
IL275418B2 (en) | 2024-07-01 |
EP4050016A1 (en) | 2022-08-31 |
CA3086186A1 (en) | 2019-06-27 |
EP3728288B1 (en) | 2022-01-19 |
BR112020012165A2 (en) | 2020-11-24 |
JP2023145727A (en) | 2023-10-11 |
US20190233468A1 (en) | 2019-08-01 |
US20220242902A1 (en) | 2022-08-04 |
CN111712510A (en) | 2020-09-25 |
MX2020006586A (en) | 2020-10-08 |
WO2019126554A1 (en) | 2019-06-27 |
SG11202005809TA (en) | 2020-07-29 |
KR20200103740A (en) | 2020-09-02 |
US11236126B2 (en) | 2022-02-01 |
HUE057850T2 (en) | 2022-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220242902A1 (en) | Methods for enhanced removal of impurities during protein a chromatography | |
US10941178B2 (en) | Method of purifying an antibody | |
US20200282332A1 (en) | Use of alkaline washes during chromatography to remove impurities | |
US20120141497A1 (en) | Methods of purifying small modular immunopharmaceutical proteins | |
US20140010820A1 (en) | Novel purification of non-human antibodies using protein a affinity chromatography | |
US20140288278A1 (en) | Chromatography process for resolving heterogeneous antibody aggregates | |
US20230060770A1 (en) | Cation exchange chromatography wash buffer | |
WO2015061526A1 (en) | Antibody purification | |
CN112313248A (en) | Method for purifying monomeric monoclonal antibodies | |
RU2773852C2 (en) | Methods for improved impurity removal during chromatography based on binding with protein a | |
US20230406881A1 (en) | Buffers and methods for purifying proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200717 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40039534 Country of ref document: HK |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20210804 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602018029895 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1463747 Country of ref document: AT Kind code of ref document: T Effective date: 20220215 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20220321 Ref country code: NO Ref legal event code: T2 Effective date: 20220119 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2907744 Country of ref document: ES Kind code of ref document: T3 Effective date: 20220426 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E057850 Country of ref document: HU |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220119 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220519 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220119 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220119 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220419 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220119 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220119 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220420 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220519 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602018029895 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220119 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220119 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220119 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220119 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220119 |
|
26N | No opposition filed |
Effective date: 20221020 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220119 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 1463747 Country of ref document: AT Kind code of ref document: T Effective date: 20220119 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230424 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221220 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20231116 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231026 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20231128 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20231010 Year of fee payment: 6 Ref country code: NO Payment date: 20231212 Year of fee payment: 6 Ref country code: MT Payment date: 20231219 Year of fee payment: 6 Ref country code: IT Payment date: 20231110 Year of fee payment: 6 Ref country code: IE Payment date: 20231009 Year of fee payment: 6 Ref country code: HU Payment date: 20231121 Year of fee payment: 6 Ref country code: FR Payment date: 20231108 Year of fee payment: 6 Ref country code: DK Payment date: 20231214 Year of fee payment: 6 Ref country code: DE Payment date: 20231024 Year of fee payment: 6 Ref country code: CZ Payment date: 20231129 Year of fee payment: 6 Ref country code: AT Payment date: 20231127 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20231121 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240111 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CY Payment date: 20231218 Year of fee payment: 6 Ref country code: CH Payment date: 20240101 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220119 |